1 2
Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program
Project for Developing Innovation Systems
Ministry of Education, Culture, Sports, Science and Technology(MEXT) Science and Technology Policy Bureau University-Industry Collaboration and Regional R&D Division Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program3-2-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-8959, Japan Tel : +81-(0)3-5253-4111 2014.03
東 京大 学The University of Tokyo
Creation of Innovation Centers forAdvanced Interdisciplinary Research Areas Program
INDEXCreation of Innovation Centers for Advanced Interdisciplinary Research Areas Program
2006 2007 2008
1
The Ministry of Education, Culture, Sports, Science and Technology (MEXT) emphasiz-
es the importance of creating continuous innovation by making the best use of its ba-
sic scientific and engineering capabilities in order to secure a sustainable competitive
advantage for Japan in the international community.
Generating new knowledge by maximizing the effects of synergy through the fusion
of different disciplines is also required in order to meet diversified social needs. Being
aware of such needs, MEXT has operated since FY 2006 a program for the “Creation
of Innovation Centers for Advanced Interdisciplinary Research Areas.”
This program is expected to create R&D centers and strengthen the capacity of re-
searchers and engineering staff shouldering next-generation needs in advanced inter-
disciplinary research areas.
The aim of this program is to overcome the so-called “valley of death” through inte-
grated industry-academia collaboration focusing on future commercialization.
Twelve centers are currently being operated in advanced interdisciplinary research ar-
eas such as nanotechnology, biotechnology, IT, and the like, as well as in fields such
as engineering, medicine, pharmacology, and physical sciences. These centers strongly
promote R&D for creating innovation with enormous social and economic impact,
such as the creation of new industries that can be expected to emerge in 10–15 years,
through not only the involvement of universities but the active participation and com-
mitment of enterprises (with a matching fund format). Products have already been
commercialized in several areas. This program can be expected to become good prac-
tices for innovation creation in Japan.
Creation of Innovation Centers for Advanced Interdisciplinary Research Areas Program
Project for Developing Innovation Systems
Project Guide 02
Locations 03
Adopted FY2006
Kyoto University Innovative Techno-Hub for Integrated Medical Bio-Imaging 04
The University of Tokyo COE for Nano Quantum Information Electronics 08
Hokkaido University 12
Tokyo Women’s Medical University 16
In-Depth Focus � 20
Adopted FY2007
Osaka University Photonics Advanced Research Center� 22
The University of Tokyo Translational Systems Biology and Medicine Initiative� 26
Tohoku University R&D Center of Excellence for Integrated Microsystems� 30
Kyushu University Innovation Center for Medical Redox Navigation� 34
Kyoto University � 38
In-Depth Focus � 42
Adopted FY2008
Yokohama City University � 44
� 48
Kobe University Innovative Bio Production Kobe (iBioK) � 52
In-Depth Focus � 56
INDEX
March 2014University-Industry Collaboration and Regional R&D Division Science and Technology Policy Bureau Ministry of Education, Culture, Sports, Science and Technology
Kyoto�U�adopted�FY2007�is�here
The Matching Program for Innovations in Future Drug Discovery and Medical Care
Advanced Interdisciplinary Center for the Establishment of Regenerative Medicine
Innovation Center for Immunoregulation Technologies and Drugs
Establishment of Research Center for Clinical Proteomics of Post-Translational Modifications
Vertically Integrated Center for Technologies of Optical Routing toward Ideal Energy Savings (VICTORIES)
National Institute of Advanced Industrial Science and Technology
2 3
ProjectsCreation of Innovation Centers for Advanced Interdisciplinary Research Areas Program
2006 2007 2008
OverviewCreation of Innovation Centers for Advanced Interdisciplinary Research Areas Program
2006 2007 2008
東 京大 学The University of Tokyo
拠 点
Tokyo Women’s Medical University
Advanced Interdisciplinary Center for the Establishment of Regenerative Medicine
Collaborating Organizations:Dai Nippon Printing Co., Ltd., Cell-Seed Inc., Hitachi, Ltd.
Tohoku University
R&D Center of Excellence for Integrated Microsystems
Collaborating Organizations : Ricoh Company, Ltd., Toppan Technical Design Center Co., Ltd., Mems Core Co., Ltd., Kitagawa Iron Works Co., Ltd., Sumitomo Precision Products Co., Ltd., Toyota Motor Corporation, The Nippon Signal Co., Ltd., Nidec Copal Electronics Corporation, Nihon Dempa Kogyo Co., Ltd., Pioneer Corporation, MEMSAS Inc., Toyota Central R&D Labs., INC., NIKKO Company, Japan Aviation Electronics Industry, Ltd., Furukawa Electric Co., Ltd., Denso Corporation
Hokkaido UniversityCollaborating Organizations : Shionogi & Co., Ltd., Hitachi, Ltd., Sumitomo Bakelite Co., Ltd., Nihon Medi-Physics Co., Ltd., Mitsubishi Heavy Industries, Ltd.
Kyushu University
Innovation Center for Medical Redox Navigation
Collaborating Organizations : JEOL Ltd., Shimadzu Corporation, M i t s u b i s h i T a n a b e P h a r m a Corporation, Taiho Pharmaceutical Co., Ltd., HOYA Corporation, Fuji Electric Co., Ltd., NOF Corporation, Kyushu Electric Power Co., Inc.
Kobe University
Innovative Bio Production Kobe (iBioK)
Collaborating Organizations : ASAHI KASEI CHEMICALS CORPORATION, EZAKI GLICO CO., LTD., Kaneka Corporation, Gekkeikan Sake Company, Ltd., COSMO OIL CO., LTD., DAICEL CORPORATION, TEIJIN LIMITED, Nagase & Co., Ltd., NITTO DENKO CORPORATION, NIPPON SHOKUBAI CO., LTD., NIPPON PAPER INDUSTRIES CO., LTD., Bio-energy Corporation, Fujicco Co., Ltd., Mitsui Chemicals, INC.
National Institute of Advanced Industrial Science and Technology
Vertically Integrated Center for Technologies ofOptical Routing toward Ideal Energy Savings (VICTORIES)
Collaborating Organizations : Nippon Telegraph and Telephone Corpora-tion, Fujitsu Laboratories Ltd., Furukawa Electric Co., Ltd., Trimatiz Ltd., NEC Corporation, Fujitsu Ltd., Fujikura Ltd., Alnair Labs Corporation, Sumitomo Electric Industries, Ltd., Kitanihon Electric Cable Co., Ltd.
Kyoto University
Innovative Techno-Hub for Integrated Medical Bio-Imaging
Collaborating Organizations : Canon Inc., Otsuka Pharmaceutical Co., Ltd.
Kyoto University
Innovation Center for Immunoregulation Technologies and Drugs
Collaborating Organizations : Astellas Pharma Inc.
Yokohama City University
Establishment of Research Center for Clinical Proteomics of Post-Translational Modifications
Collaborating Organizations : Medical ProteoScope Co., Ltd., Lion Corporation, FUJIFILM Corporation, Eisai Co., Ltd., FANCL Corporation, TOSOH Corporation, Sekisui Medical Co., Ltd., Toyama Chemical Co., Ltd, CellFree Sciences Co., Ltd.
Osaka University
Photonics Advanced Research Center
Collaborating Organizations : Shimadzu Corporation, Sharp Corporation, Nitto Denko Corporation, Mitsubishi Chemical Group Science and Technology Research Center, Inc., IDEC Corporation
The University of Tokyo
COE for Nano Quantum Information Electronics
Collaborating Organizations : Sharp Corporation, NEC Corpo-ration, Hitachi, Ltd., Fujitsu Laboratories Ltd., QD Laser, Inc.
The University of Tokyo
Translational Systems Biology and Medicine Initiative
Collaborating Organizations: Forerunner Pharma Research Co., Ltd., Olympus Cor-poration, Sekisui Medical Co., Ltd., Toray Industries Inc., Mitsubishi Tanabe Pharma Corporation, Hitachi Aloka Medical, Ltd., Nikon Corporation, Kowa Company, Ltd.
Innovative Bioproduction KOBE
Implementation Scale
Implementation Period
In the 3 years before the review About 300 million yen per year
After full-scale implementation About 500–700 million yen per year
During the initial 3 years, centers that have made proposals are shortlisted.A review is conducted in the 3rd year (after 2.5 years and 3.5 years) to narrow down the list by two-thirds.Themes that proceed to actual implementation shall continue to be imple-mented over the next 7 years. A total of 21 themes were selected between 2006 and 2008. Currently, 12 of these are underway.
Universities, inter-university research institute corporations, national research institutes, and incorporated administrative agencies(Participants are obliged to come up with joint proposals with the industrial world, which is also expected to shoulder a reasonable amount of the cost.)
Participants
先端融合拠点形成
次世代を担う研究者・技術者の育成
産学協働で社会・経済的インパクトのある
イノベーションを推進する拠点を形成
要素技術(企業、大学)の
参画
他先端領域との連携
協働体制の構築
開発力(企業)
先端的なコア技術(大学)
ER1 R2
CNB
R3R4N
Y
Creation of Centers for Advanced Interdisciplinary ResearchCreate centers to promote innovations that have social and economic impact
through collaboration between industry and academia.
Tie-ups in otheradvanced areas
Advanced core technologies
(universities)
Development capabilities (companies)
Inclusion ofcomponent technologies (company, universities)
ER1 R2
CNB
R3R4N
Y
Construction ofcollaboration system
Development ofresearchers and engineering
staff to shoulder next-generation needs
This program aims to support the creation of innovation centers that have significant social and
economic impact, such as the generation of new industries. The program will achieve this goal by
matching academia with industries in advanced interdisciplinary research areas considered to be
especially important for innovation.
To overcome the “valley of death,” creating R&D innovation centers to conduct basic research through industry-academic collaboration
Based on collaboration between industry and academia, create a system with the seeds sown by universities as its core, in order to realize innovation in advanced interdisciplinary research areas.
The Matching Program for Innovations in Future Drug Discovery and Medical Care
54
Cre
atio
n o
f Inn
ova
tion
Ce
nte
rs for A
dva
nc
ed
Inte
rdisc
iplin
ary R
ese
arc
h A
rea
s Prog
ram
Kyoto UniversityInnovative Techno-Hub for Integrated Medical Bio-Imaging
Fusion of Kyoto University’s integrated scientific-technological knowledge and excellent clinical research achievements with the collaborating organization’s technical strengths in product development to create the social value through the realization of innovative imaging-diagnosis techniques and modalities.
ORGANIZATION
Name Kyoto University
U R L http://ckpj.t.kyoto-u.ac.jp/?lang=en
Address Yoshida Hon-machi, Sakyo-ku, Kyoto 606-8501, Japan TEL. +81-75-753-4896 FAX. +81-75-753-9147Overall Person-in-charge Hiroshi Matsumoto (President, Kyoto University)
Researcher (Representative) Nagahisa Yoshimura (Professor, Graduate School of Medicine)/
Teruyuki Kondo (Professor, Advanced Biomedical Engineering Research Unit)
Implementation Period FY2006 – FY2015
Collaborating Organizations : Canon Inc., Otsuka Pharma-
ceutical Co., Ltd.
■ 7th Year (FY2012)
1 A clinical trial of the prototype equipment of retinal optical
imaging system (OCT/SLO) has been started for the product as-
sessment.
2 The higher functions and technologies for the integration of
ultrasound and optical imaging (US/PAT) have been established,
and the prototype equipment of photoacoustic mammography
(PAM) has been introduced.
3 The sensitivity of atomic magnetometers (AMMs) has been
improved. Compact module-type AMMs have been fabricated.
Bio-magnetic signals as well as MR signals in ultra-low magnetic
fields have been observed.
■ After Project Ends (around 2017)
1 Industrial application of the basic, collaborative and interdisci-
plinary researches should be continued at a world top-level base
institution of Kyoto University.
2 The talented researchers in interdisciplinary research areas of
medicine and engineering, who can play an active and important
part in industry and the medical institutions, should be fostered
through the clinical cooperation.
■ 10th Year (FY2015)
1 Through the collaboration with IIIM, OCT and SLO equipment
with new functions will be realized.
2 The development of the integrated image diagnosis system
for US will be completed, and the prototype equipment with a
new principle/multi-modality based on PAT imaging will be es-
tablished.
3 A fused imaging system to detect multiple bio-magnetic sig-
nals with ultra-sensitive AMM modules will be realized.
4 The innovative molecular probes will be developed, and the
strictly selected molecular probes will be applied to pre-clinical
trials.
Collaboration System1
2 Overall Concept
The CK project combines Kyoto University’s
integrated scientific-technological knowledge
and excellent clinical research achievements
with the Canon Inc.’s technical strengths in
product development. Since 2012, Otsuka
Pharmaceutical Co., Ltd. has participated in
the project to accelerate the development of
molecular imaging probes.
The aim of the project for ten years is the
realization of innovative imaging-diagnosis
techniques and equipment including the de-
velopment of innovative molecular imaging
probes. Ultimately the program seeks to con-
tribute to the creation of “healthy society” by
promoting cutting-edge research and devel-
opment, while fostering talented researchers
in interdisciplinary research areas of medicine
and engineering.
The university system for the intellectual prop-
erty has been reformed to accelerate the real-
ization of the invented technologies through
the academia-industry collaboration. The
base institutions for the project are the Kyoto
University Hospital including Clinical Research
Center for Medical Equipment Development
(CRCMeD) on Kyoto University’s Yoshida cam-
pus, the Int’tech Center on Katsura campus,
and Canon Inc. in Shimomaruko, Tokyo. A
world top-level base institution will be estab-
lished at Kyoto University to foster talented
researchers in interdisciplinary research areas
of medicine and engineering.
RESEARCH THEME
Development of a retinal optical imaging system (OCT/
SLO) that simultaneously achieves high definition and a
high imaging speed
Establishment of the highly advanced medical care to de-
tect complications of lifestyle-related diseases appeared in
the fundus and retinal diseases
Social Value Improvements of the Quality of Life (QOL)
of patients through the early diagnosis of fundus and reti-
nal diseases that may cause vision loss.
Economic Value Contribution to the reduction of both
medical expenses and economic losses caused by severe
vision impairment
Expected Market Scale/Expected Achievement Period
80 billion yen (global market scale)/4 years after end of
implementation period
Results to Date The potential now exists to detect initial
changes in the key ophthalmological diseases and vascu-
lar lesions in the lifestyle diseases through the research
and development of the “high-speed and wide-angle
prototype OCT” with a
5 μm horizontal reso-
lution capability and a
“High-Resolution pro-
totype AOSLO” based
on aberration error-cor-
rection technology.
76
Kyoto UniversityInnovative Techno-Hub for Integrated Medical Bio-Imaging
1 Development of Retinal Optical Imaging Technologies (OCT/SLO)
Development of novel technologies of ultra-sensitive
optically-pumped atomic magnetometers (AMMs) not
requiring cryogenic cooling, compact and array AMMs,
and related signal processing
Application of such technologies to ultra-low field MRI
and bio-magnetic imaging, represented by magnetoen-
cephalography and magnetocardiography
Social Value New diagnostic methodologies through
development of a multimodal bio-magnetic imaging sys-
tem with MRI
Economic Value Creation of a new market by the devel-
opment of a compact and handy multimodal bio-mag-
netic imaging system
3 Development of Magnetic Sensing/MR Imaging Technologies with AMM (AMM/MRI)
Implements for a clinical decision support system using
a comprehensive dataset consisting of multiple imaging
modalities and various kinds of clinical information
Social Value Reducing doctors’ workload and improve-
ment of the accuracy of clinical diagnosis
Economic Value The system encourages people to
utilize their own personal healthcare information to
improve the quality of medical treatment for them.
Deployment of the system as a social infrastructure
creates a big business chance, and, at the same time,
lessens the burden of medical bill on the society.
Expected Market Scale/Expected Achievement Period
1 trillion yen (global market scale)/4 years after end of
implementation period
Results to Date We have built a large database on lung
nodules, and computer inference system using the data-
base.
Subsequently, we are currently verifying the clinical ben-
efit of the system, and also developing a computer aided
diagnosis system for OCT imaging.
5 Development of Computer Aided Diagnosis System (IIIM)
Collaborating Organizations : Canon Inc.
Development of novel ultrasound-based technologies
with excellent features such as non-invasive, real-time,
compact, and handy to acquire information on tissue
characteristics and higher-order functions
Commercialization of a new imaging technology for bi-
ological functions that integrates ultrasound and optical
imaging (US/PAT)
Social Value Improvement of diagnostic accuracy for
breast cancer of young ladies as well as seniors
Economic Value Widespread use of new modality, PAM,
even in small clinics, which greatly contribute to reduce
medical cost and improve patient benefit
Expected Market Scale/Expected Achievement Period
800 billion yen (global market scale)/4 years after end of
implementation period
Results to Date We have succeeded in developing the
ultra-high resolution technology in ultrasound (US) im-
aging through adaptive signal processing and the tissue
property imaging technology based on the measurement
of tissue viscoelasticity and 2D displacement vector. We
have just started a clinical research of photoacoustic
mammography (PAM), and
obta ined images of oxy-
gen-saturated and unsatu-
rated haemoglobins in the
blood vessels of the breast
cancer.
2 Development of Ultrasound and Photoacoustic Imaging Technologies (US/PAT)
Collaborating Organizations : Canon Inc.
A performance enhancement of minimally-invasive
probe-targeted imaging based on “optical” and “mag-
netic resonance” (MR) imaging
Development of innovative molecular probes based on
new principles for imaging of biological functions and
metabolisms
Social Value The use of innovative molecular probes
with new principles reduces the burden on patient
through optimal medical treatment based on early cancer
detection and malignancy diagnosis.
Economic Value Creation of the market for molecular
probes based on new principles for photoacoustic (PA)
imaging as well as probe-targeted focal magnetic reso-
nance (MR) imaging
Expected Market Scale/Expected Achievement Period
150 billion yen (global market scale)/4 years after end of
implementation period
Results to Date We have developed four kinds of highly
functional photoacoustic (PA) imaging probes based on
dye-containing nanoparticles by fusion of optical and
ultrasound imaging technologies. Otsuka Pharmaceutical
Co., Ltd. has participated in this project to accelerate the
pre-clinical trials of them. On the other hand, we have
succeeded in developing 13C/15N-labelled poly(2-meth-
acryloyloxyethylphosphorylcholine), 13C/15N-PMPC, probe,
which accumulates
very selectively and ef-
ficiently in the tumour
b y t h e e n h a n c e d
permeability and re-
tention (EPR) effect,
and realizes the first
probe-targeted focal
MRI.
4 Development of Molecular Probes
Collaborating Organizations : Canon Inc., Otsuka Pharmaceutical Co., Ltd.
Collaborating Organizations : Canon Inc.
New Optical Coherence Tomography Equipment (OCT-HS100)
An Image of the Breast Cancer Examination with PAM
Expected Market Scale/Expected Achievement Period
600 billion yen (global market scale) /4 years after end of
implementation period
Results to Date We have developed the state-of-the-art
atomic magnetometers achieving the top level sensitivity
in the world. We also have developed a compact mod-
ule-type atomic magnetometer. Using the atomic mag-
netometers, NMR signals have been observed under low
magnetic field conditions. In addition, both the imaging
of magnetocardiographic distributions and the measure-
ment of neuro-magnetic fields
are successful in humans.
A Module-type Atomic Magnetometer
A Photoacoustic-Magnetic Resonance Dual Im-aging Probe
Collaborating Organization : Canon Inc.
Aspect Analysis Based on the Features of Lung Nodule
98
Cre
atio
n o
f Inn
ova
tion
Ce
nte
rs for A
dva
nc
ed
Inte
rdisc
iplin
ary R
ese
arc
h A
rea
s Prog
ram
The University of TokyoCOE for Nano Quantum Information Electronics
ORGANIZATION
Name The University of Tokyo
U R L http://www.nanoquine.iis.u-tokyo.ac.jp/index-e.html
Address 4-6-1, Komaba, Meguro-ku, Tokyo TEL. 03-5452-6920 FAX. 03-5452-6921
Development of technologies to realize a safe, low energy consumption, and ambient IT society through a combination of nanotechnology, quantum science, IT, and electronics
Overall Person-in-charge Junichi Hamada (President, the University of Tokyo)
Researcher (Representative) Yasuhiko Arakawa (Professor, Institute of Industrial Science)
Implementation Period FY2006 – FY2015
Collaboration System1
2 Overall Concept
B y t h e d e v e l -
opment of in-
novat ive bas ic
technologies and
the nu r tu r i ng
of research manpower, we aim to realize a
next-generation information network system
that satisfies the ultra-broadband, ultra-safe
and ultra-energy-efficient (low power con-
sumption) requirements of the ubiquitous
information society of the future.
Within the university we are consolidating
knowledge on nanotechnology, quantum
science, and IT, and striving to build up both
international and national collaborations
with influential researchers and institutions
within and outside Japan. Our core research
is being carried out on next-generation nano-
electronics, focusing on quantum dot lasers,
nano-quantum information electronics such
as encrypted quantum communications, and
the basic technologies in quantum informa-
tion science that support all of these areas.
Advanced lectures that provide a broad over-
view of these topics are given in the science
and engineering schools, and intensive indus-
try-orientated lectures are organized with col-
laborating organizations in order to develop
well-rounded personnel.
Intellectual property agreements among the
collaborating organizations are unified, and
we are also carrying out Intellectual property
reform making use of special zones within the
university. We are striving to attract excellent
researchers to the center.
■ 7th Year (FY2012)
1 Expand the market for quantum dot lasers and build a foun-
dation for the creation of innovation using quantum mechanical
devices.
2 Verify the high-speed behavior of organic CMOS circuits
and establish the basic technologies for large-area organic
electronics.
3 Achieve quantum key distribution over long distances (i.e., a
transmission distance of 50 km) using single-photon technologies
and demonstrate commercialization possibilities for encrypted
quantum communications.
■ 10th Year (FY2015)
1 Expand the market for industrial and consumer applications of
quantum dot lasers beyond telecommunication technologies.
2 Establish technologies for low-voltage, high-speed organic
CMOS circuits, large-area organic electronics, and high-durability
organic transistors.
3 Verify the possibility of increasing the efficiency of solar cells
using quantum dots (creating innovative technologies in renew-
able energy).
■ After Project Ends (around 2020)
1 Achieve greater mass production and market expansion for
quantum dot lasers, and an enlargement of the business scope
for optical electronics including silicon photonics as core devices.
2 Expand the market for organic electronics products.
3 Commercialize single-photon quantum key distribution tech-
nologies that guarantee absolute safety within a metropolitan
network (~100 km).
Collaborating Organizations : Sharp Corporation, NEC Cor-
poration, Hitachi, Ltd., Fujitsu Laboratories Ltd., QD Laser, Inc.
RESEARCH THEME
Research and development on increasing the output,
speed, and performance of quantum dot lasers for com-
munication purposes is on-going. Research and devel-
opment on other applications besides communications
is also being conducted. Such applications include sol-
id-state laser excitation light sources for material process-
ing, sensor light sources for application at high tempera-
ture (200°C), high-output/high-speed modulated green,
yellow-green, and orange visible semiconductor lasers
using second harmonic generation (SHG), and lasers for
optical connections between LSI chips, etc.
Social Value Due to their low cost, low power con-
sumption and excellent temperature stability, quantum
dot lasers will facilitate environmental friendly operation
and hence provide competitive strengths for investment
in communications infrastructure.
Economic Value A new business model can also be
found in using cheap GaAs substrates, consumer man-
ufacturing lines, EMS, etc., with the possibility of tak-
ing over the current market for quantum well lasers.
Expected Market Scale/Expected Achievement Period
About 100 billion yen (global) 3 years after the end of
the implementation period
Results to Date For communication applications, lasers
with a maximum modulation speed of 25 Gbps and are
stable up to temperatures of 20–70°C have been pro-
duced. For sensing applications, compact visible laser
modules (0.5 cc) that
can work at temper-
atures up to 220°C
a n d h i g h - o u t p u t ,
high-speed green la-
sers that exceed 100
mW in power have
also been realized.
1110
The University of TokyoCOE for Nano Quantum Information Electronics
1 Development and deployment of quantum dot laser technologies
3 Development of basic technologies for high efficiency quantum dot solar cells
High efficiency energy conversion is expected for quan-
tum dot solar cells, and systematic research and devel-
opment starting with basic areas such as new materials,
nanostructures, and functionalities are being carried out
(with a focus on using the intermediate band) in order to
investigate theoretical possibilities.
Social Value Raising the conversion efficiency above a
certain level will put a stop to the current cost compe-
tition and usher in a paradigm shift when quantum dot
solar cells are built into mobile devices, OA equipment,
cars, and the like.
Economic Value Create new value and cost competitive-
ness, leading to an expansion in the market base for so-
lar power generation.
Expected Market Scale/Expected Achievement Period
About 1 trillion yen (global) 15 years after the end of the
implementation period
Results to Date A basis study of quantum dot solar cells
has been conducted. Previously, the highest theoretical
efficiency limit was thought
to be 63%, but this has
been updated to 75% in
theory. A prototype quan-
tum dot model achieved a
maximum of 18.7% and
demonstrated for the first
time that there is no de-
terioration when realizing
flexibility.
2 Organic CMOS circuits that achieve high speeds with low power consumption
Silicon semiconductors are the main type of semiconduc-
tors in current use. Organic semiconductors may be more
flexible, cheaper, and advantageous, although there is
a need to overcome the low speed and high voltage re-
quired before market expansion can take place. In order
to create organic CMOS circuits, a variety of technolo-
gies (starting with basic technologies) are currently being
accumulated.
Social Value Organic circuits are flexible and cheap, and
once their performance reaches a higher level, they will
begin to appear in consumer-related products. Following
this, products including drive circuits such as displays will
use only organic semiconductors.
Economic Value As today’s development of semicon-
ductors relies on silicon CMOS, compatibility with this
technology will enable the realization of high-speed,
low-power-consumption organic circuits, which will in
turn create new markets.
Expected Market Scale/Expected Achievement Period
About 2 trillion yen (global) 5 years after the end of the
implementation period
Results to Date Using a p-type pentacene organic TFT
and the increased mobility in n-type C60, a 5-step CMOS
ring oscillator with a cut-off frequency exceeding 200
kHz has been achieved (this
value is the highest in the
world, and is sufficient for
use in RFID). A low-cost
so lu t ion manufactur ing
method for C60 has also
been developed.
Quantum dot solar cells
Quantum key distribution technology using single photons in the communi-
cations wavelength band
Collaborating Organizations : Fujitsu Laboratories Ltd., QD Laser, Inc.
Quantum dot laser
Organic CMOS circuit
Collaborating Organizations : Sharp Corporation, NEC Corporation
Collaborating Organizations : Sharp Corporation
Collaborating Organizations : NEC Corporation, Hitachi, Ltd., Fujitsu Laboratories Ltd.
A Quantum key distribution technology using single pho-
tons in the 1.5 μm band with performance that is top of
its class has been achieved by the promotion of open in-
novation that transcends the barriers among competing
companies, and collaboration with NICT (National Insti-
tute of Information and Communications Technology).
Social Value Compared to quasi-single photon meth-
ods, this method is able to simplify system configuration
and safety analysis by a wide margin, and will result in
a breakthrough in the commercialization and spread of
quantum cryptography communication.
Economic Value The economic impact from ensuring the
absolute safety and reliability of communications will be
enormous.
Expected Market Scale/Expected Achievement Period
About 40 billion yen (global) 5 years after the end of the
implementation period
Results to Date The multi-photon occurrence rate,
which determines whether or not eavesdropping is possi-
ble, has been limited to 1/500 of the classical light ratio.
Single photon generation in the 1.5 μm band with the
highest purity in the world has been achieved. Together
with a superconducting detector, a new quantum cryp-
tography system has been developed, and quantum key
distribution tests that exceed 100 km (twice the previous
range) have been successfully conducted.
Development of single-photon quantum cryptography distribution technologies in the com-munications wavelength band
4
1312
Cre
atio
n o
f Inn
ova
tion
Ce
nte
rs for A
dva
nc
ed
Inte
rdisc
iplin
ary R
ese
arc
h A
rea
s Prog
ram
Hokkaido UniversityThe Matching Program for Innovations in Future Drug Discovery and Medical Care
ORGANIZATION
Name Hokkaido University
U R L http://www.cris.hokudai.ac.jp/cris/innovahome/index_e.html
Address Kita-8, Nishi-5, Kita-ku, Sapporo-shi, Hokkaido TEL. +81-(0)11-706-9188 FAX. +81-(0)11-706-9190
Fusion of next-generation drug discovery using protein modification technologies and personalized medicine using light and radiation measurement technologies
Overall Person-in-charge Keizo Yamaguchi (President, Hokkaido University)
Drug Discovery Research Project Leader : Yasuyuki Igarashi (Specially Appointed Professor, Frontier Research Center for Post-genome Science and Technology ) / Medical Care Research Project Leader : Nagara Tamaki (Professor, Graduate School of Medicine)
Implementation Period FY2006 – FY2015
Collaborating Organizations : Shionogi & Co., Ltd., Hitachi,
Ltd., Sumitomo Bakelite Co., Ltd., Nihon Medi-Physics Co.,
Ltd., Mitsubishi Heavy Industries, Ltd.
■ 7th Year (FY2012)
Establish basic technologies for drug discovery such as new li-
gand screening technologies, etc., and multiple pharmaceutical
candidate compounds, and identify disease-related biomarker
candidates. Link advanced life sciences to medical device engi-
neering as well as medical personnel in hospitals to companies in
equivalent positions for future drug discovery and interdisciplin-
ary medical centers. Relevant areas include RI molecular probe
exploration, quantitative diagnosis using semiconductor PET, and
radiation therapy plan combining PET images with other modali-
ty images.
■ After Project Ends (around 2016)
Link up with university hospitals, support organizations for trans-
lational research and chemical compound libraries, etc., build a
platform that will serve as a foundation for next-generation drug
discovery research and medical device development, create “fu-
ture drug discovery and medical care centers” (provisional name)
for R&D that private companies cannot undertake on their own,
promote technology transfers between industry and academia,
and generate new innovations in a sustainable manner.
■ 10th Year (FY2015)
Make use of new technologies to establish a system for the con-
tinuous creation of next-generation pharmaceutical candidate
compounds that meet clinical needs. Establish a translational
research system for clinical evaluation of the usefulness of new
drug candidates, RI probes, biomarkers. Realize new personal-
ized medicine that is beneficial for patients based on these inno-
vations.
Collaboration System1
2 Overall Concept
Create an international center for human re-
sources development and research focusing
on a gateway to establish a foundation for
drug discovery that enables potential drug
candidates to be created continuously, and to
realize non-invasive personalized medical care
that is beneficial to patients. Link interdisci-
plinary research on life sciences and advanced
medical engineering to advanced medical
treatment, promote system reform in con-
nection with the university’s involvement in
development work, and streamline the drug
discovery and medical device development
process. Promote independent research and
development that is difficult for individual
companies to undertake due to the large risks
involved. Develop young, exit-oriented young
researchers by employing those from both
within and outside Japan and by employing
corporate researchers as graduate school
lecturers, faculty staff, etc. Implement vari-
ous system reforms to encourage corporate
researchers to obtain postgraduate degrees,
and also promote mutual personnel exchange
between industry and academia. Organize
international symposiums on a regular basis
and promote interdisciplinary research with a
global outlook.
Researcher (Representative)
RESEARCH THEME
1514
Hokkaido UniversityThe Matching Program for Innovations in Future Drug Discovery and Medical Care
Integrating PET technology with image- guided radiation therapy equipment
Results to Date A product concept for the parallel
plane, PET-mounted radiation therapy equipment that
allows cancer imaging to be
carried out during treatment
by combining an X-ray therapy
machine with a PET machine
has been established.
Social Value Build a new foundation for drug discovery
and the development of diagnostic and therapeutic de-
vices through manpower exchanges and interdisciplinary
research in personalized medical care using next-gener-
ation drug discovery and photonic/RI imaging technolo-
gies, and contribute to improvement in the patient quali-
ty of life and treatment results for diseases.
Economic Value The greatest economic value lies in the
university being able to take the lead in undertaking
research and development that is deemed too risky for
individual companies to embark upon, and this value
cannot be quantified. To penetrate the markets envis-
aged below, while realizing product development based
on the technologies cultivated in the innovation center, a
process that extends from R&D all the way to clinical ap-
plications via translational research is also being realized
within a single university campus. Doing so will further
increase the economic value for collaborating organiza-
tions to choose a university in Japan rather than an over-
seas facility as a platform partner.
Expected Market Scale/Expected Achievement Period
Infectious disease and metabolic diseases drugs: 250–
500 billion yen/8–12 years after end of implementation
period; glycan microarray: 2.5 billion yen in 2030; PET/
SPECT; 15–230 billion yen in 2030; new RI probe: 4–5
billion yen in 2030; radiation therapy equipment: 72–78
billion yen in 2030
Human Resources Development Capable personnel with a
thorough understanding of life science, drug discovery,
medicine, and other areas who are able to work as lead-
ers in multidisciplinary research areas are being cultivated
in the university and companies. Foreign researchers and
researchers from collaborating organizations developed
at this center are working as specially appointed pro-
fessors or company management, and the number of
invitations extended to the center’s researchers to give
lectures at international conferences as well as the num-
ber and size of developmental research grants acquired
are increasing.
Collaborating Organization : Mitsubishi Heavy Industries, Ltd.
4 Research and development on new RI probes
Results to Date In response to the PET innovation, a
new RI probe has been developed, and R&D using animal
disease models is in progress. A bridge towards clinical
applications has been built within the university, allowing
clinical evaluation to be carried out in collaboration with
research and support organizations.
Collaborating Organization : Nihon Medi-Physics Co., Ltd.
Towards the establishment of a drug discovery foundation that enables the continuous creation of potential drug candidate compounds
Make use of the strengths of Hokkaido University in researches of lipids, glycans, structural biology, etc., to explore new
potential drug targets, conduct drug discovery research based on advanced protein structures, promote investigative re-
search and development of research tools for identifying diseases and creating biomarkers for drug discovery, and take
on the challenge of creating potential pharmaceutical compounds that can advance to the clinical trial stage, with the
ultimate aim of establishing a drug discovery foundation that enables the continuous creation of potential drug candidate
compounds. In addition, expand basic and clinical research with a focus on the development of regenerative medicine.
Collaborating Organization : Hitachi, Ltd.
Development of non-invasive personalized medical care beneficial to patients
Based on component technologies such as photonic/RI imaging technology, aim for the construction of a new medical
process and development of medical devices that make non-invasive personalized medical care that is beneficial to patients
a reality, and take up the challenge of conducting R&D in various areas in partnership with collaborating organizations.
Results to Date The use of the virus library in Hokkaido
University contributed to the development of anti-influ-
enza drugs launched in 2010. Based on the results ob-
tained in this project, one potential drug compound has
also entered pre-clinical trial testing. Besides this, three
new drug discovery programs
have also been started (for two
infectious disease drugs and
one lifestyle-related disease
drug). Furthermore, drug dis-
covery group has started a bio-
1 Development of pharmaceutical products with new action mechanisms
2 Development of new carbohydrate microarray
Results to Date Based on the
results obtained in this project,
Sumitomo Bakelite Co., Ltd.
started sales of a carbohydrate
microarray in FY2011.Collaborating Organization : Sumitomo Bakelite Co., Ltd.
Collaborating Organization : Shionogi & Co., Ltd.
marker exploration project with Shionogi & Co., Ltd. that
is spearheaded by its wholly owned U.S. subsidiary Ezose
Sciences, which was established in Feb 2009.
Results to Date Research that applies semiconductor
technology in medical treatment has been advanced
through the development and clinical application of the
world’s first PET/SPECT that uses a semiconductor de-
tector. Due to the high-definition of the detector, local
diagnosis of the hypoxia region in head and neck cancer
is made possible, and this has been applied in radiation
therapy planning. As a ripple effect, this has also proven
useful in the detection of radia-
tion after the Great East Japan
Earthquake and the commercial
sales of semiconductor radiation
detectors and modules.
Development of high-definition PET/SPECT using semiconductor detection technology, and related clinical applications
3
5
1716
Cre
atio
n o
f Inn
ova
tion
Ce
nte
rs for A
dva
nc
ed
Inte
rdisc
iplin
ary R
ese
arc
h A
rea
s Prog
ram
Tokyo Women’s Medical UniversityAdvanced Interdisciplinary Center for the Establishment of Regenerative Medicine
ORGANIZATION
Name Tokyo Women’s Medical University
U R L http://www.twmu.ac.jp/ABMES/CSTEC/ja
Address 8-1, Kawada-cho, Shinjuku-ku, Tokyo TEL. 03-3353-8111 FAX. 03-3359-6046
Creation of innovation centers for the development, spread, and industrialization of world-leading and multi-disciplinary regenerative technology through the fusion of cell sheet engineering technology and medical science
Overall Person-in-charge Hiroshi Kasanuki (President, Tokyo Women’s Medical University)
Researcher (Representative) Teruo Okano (Professor, Tokyo Women’s Medical University)
Implementation Period FY2006 – FY2015
Collaborating Organizations : Dai Nippon Printing Co., Ltd.,
CellSeed Inc., Hitachi, Ltd.
■ 7th Year (FY2012)
1 Carry out the world’s first human clinical research on cell sheet
regeneration for esophageal cancer, heart failure, periodontal
disease, pneumothorax, and the like, in addition to achieving the
world’s first approval for cornea regeneration using cell sheets.
2 Establish a manpower development and support system with
on-the-job trainings of new types of regenerative medicine doc-
tors and researchers based on a new setup for industry-academia
collaboration and interdisciplinary medical engineering.
■ After Project Ends (around 2025)
1 Regenerative medicine using cell sheets for a variety of tissue
and internal organs will be made available to patients at clinical
sites, including those overseas.
2 A regenerative medicine industry using cell sheets to achieve
radical treatment will pull along the pharmaceutical industry and
achieve greater development through the fusion of advanced
technologies and new fields.
■ 10th Year (FY2015)
1 Promulgate the use of cell sheets worldwide in addition to
promoting clinical research and clinical trials in regenerative
medicine using cell sheets for various tissue and internal organs.
2 Achieve a breakthrough that exceeds traditional boundaries
in 2D tissue cultivation and establish the basic technologies for
realizing organ regeneration after tissue regeneration. Promote
the sharing of ideas, technologies, and aims among doctors and
researchers and create industrial innovations for a society that is
based on regenerative medicine using cell sheets.
Collaboration System1
2 Overall Concept
Regenerative medicine is attracting much
attention as a next-generation radical cure
amid heightening expectations for treatments
to substantially improve the QOL of patients
suffering from serious ailments and intrac-
table diseases. This center aims to become
a research center for creating innovations
that integrate various advanced technologies
across different domains deemed necessary
for making regenerative medicine truly feasi-
ble. We have already created “cell sheet engi-
neering,” and after verifying its effectiveness
and safety in animal experiments, we have
been successful in treating the ailments of
patients. This socially and medically unprece-
dented treatment method has been achieved
through the combined efforts of many re-
searchers and doctors in different domains,
and a next-generation, interdisciplinary
medical engineering center that has hitherto
not been seen has been formed. In order to
further develop and spread this innovation,
industrialization through mass production
and generalization of the existing system is
necessary. Further manpower development
and building of international competitiveness
is aimed for, together with the collaborating
organizations.
RESEARCH THEME
19
3 Development of support technologies for medical treatment using cell sheets
Develop highly functional cell cultivation medium, auto-
matic culture apparatus, and cell sheet transplant devic-
es, etc., that are necessary to realize true regenerative
medicine based on a fusion of cell sheet engineering and
cutting-edge technologies owned by collaborating or-
ganizations, as well as establish support technologies for
regenerative medicine so as to implement the cell sheet
production process and transplant process safely and ef-
ficiently.
Social Value Overseas sales of a temperature-respon-
sive culture dish were started via the U.S. company Ther-
mo Fisher Scientific in Nov 2008 (see figure). By further
developing automatic culture apparatus and transplant
devices, regenerative medicine technologies can prolifer-
ate rapidly.
Economic Value These technologies all aim to realize cell
sheet treatment at an industrial level, and the econom-
ic value brought about by these mediums and devices
which are required for widespread proliferation of the
technologies is expected to be high.
Expected Market Scale/Expected Achievement Period
Temperature-responsive culture dish: 33 billion yen/5
years after end of implementation period; automatic
culture apparatus: 4.5 billion yen/10 years after end of
implementation period, cell sheet transplant device: 6.0
billion yen/10 years after end of implementation period
Results to Date Technology that can produce a tem-
perature-responsive culture dish with high efficiency has
been established through a tie-up between Dai Nippon
Printing Co., Ltd. and CellSeed Inc. In addition, Hitachi,
Ltd. has also produced a prototype of an automatic cul-
ture apparatus that meets GMP requirements. Stable
production of cell sheets using this equipment has been
verified with the cooperation of Tokyo Women’s Medical
University.
18
Tokyo Women’s Medical UniversityAdvanced Interdisciplinary Center for the Establishment of Regenerative Medicine
1 Clinical application using a variety of cell sheets and development of peripheral projects
We believe it is our duty to overcome illnesses that cur-
rently cannot be cured by conducting clinical research
based on achievements in basic research to verify effec-
tiveness and safety. Having developed the world’s first
treatment method using cell sheet engineering in Japan,
we aim to spread the use of this treatment method Ja-
pan worldwide.
Social Value By realizing and spreading the use of
regenerative medicine, it is possible to reduce medical
costs in addition to markedly improving the QOL of pa-
tients.
Economic Value The cornea, myocardium, esophagus,
and periodontal market exceeds 1 trillion yen worldwide,
and thus the economic impact will be great if these
illnesses can be cured using cell sheet engineering.
Expected Market Scale/Expected Achievement Period
Cornea: 4.5 billion yen/3 years after end of implementa-
tion period; esophagus: 60.4 billion yen/5 years after end
of implementation period: Periodontal: 17.3 billion yen/5
years after end of implementation period
Results to Date Clinical research using cell sheets has
started in Japan in various domains such as the cornea,
heart, esophagus, periodontium, and cartilage in accord-
ance with the ‘Guidelines on clinical research using hu-
man stem cells’. Clinical trials on the regeneration of the
esophagus have been completed in Japan and overseas
expansion has been started together with the transfer
of technology to the Karolinska Institute in Sweden. In
order to build the foundation and the popularization of
cell sheet treatment, clinical research using autologous
oral mucosa cell sheets transported over long distances
from the Tokyo Women’s Medical University has begun
in Nagasaki University.
2 Basic research using a variety of cell sheets
The establishment of a drug discovery evaluation model
for heart diseases and the production and transplant of
myocardium tubes, pancreatic sheets, liver cell sheets,
and the like for the treatment of Type I diabetes, haemo-
philic diseases, and other ailments are underway as basic
research using cell sheets. New uses for hematopoietic
stem cells that are expected to be a cell source are also
being developed for regenerative treatment.
Social Value A drug discovery evaluation model using
myocardium tubes can be used for ex vivo drug discovery
evaluation. Pancreatic and liver cell sheets will also free
patients suffering from Type I diabetes and haemophilia
from drug administration and
help reduce medical costs.
Economic Value T h e g l o b a l
market for heart disease treat-
ment drugs is said to be 380
billion yen, and thus the eco-
nomic effect will be large if
myocardium tubes can be used
as a drug discovery evaluation
model. In the case of diabetes and hemophilia, frequent
drug administration will become unnecessary, and thus
the QOL of patients can be improved together with a
Collaborating Organizations : CellSeed Inc.
substantial reduction in medical costs.
Expected Market Scale/Expected Achievement Period
Myocardial tubes: 38 billion yen/3 years after end of im-
plementation period; liver, pancreas, hematopoietic stem
cells: 10 billion yen/10 years after end of implementation
period
Results to Date Through the extension load on the tu-
bular myocardial tissue produced in vivo, an increase in
expression in the swelling of the myocardial cells and
vascular endothelial growth factor due to this can be ob-
served to a significant degree. Myofibrillar formation and
developed mitochondria can be observed as well. After
transplanting pancreatic cell sheets subcutaneously into
mice that have developed diabetes, it was observed that
the blood sugar level had normalized in all cases.
Collaborating Organizations : Dai Nippon Printing Co., Ltd., CellSeed Inc., Hitachi, Ltd.
Collaborating Organizations : CellSeed Inc.
Myocardium tube
pancreas liver
In-Depth Focus 04 Tokyo Women’s Medical University
04
03
In-Depth Focus 03 Hokkaido University
In-Depth Focus 02
02
01
In-Depth Focus 01 Kyoto University
The University of Tokyo 東 京大 学The University of Tokyo
New Imaging-Diagnosis Equipment — Optical Coherence TomographyThe research group’s breakthrough in Optical Coherence Tomography
(OCT), simultaneously bringing further improvements in resolution and
imaging speed, the OCT-HS100 marketed by Canon in Sep. 2012, is
expected to lead to a high level eye fundus diagnostic modality with the
ability to detect signs of sight threatening diseases appearing on the
fundi.
Clinical Research in Progress — Photoacoustic Mammography(introduced with a newspaper, the Nihon Keizai Shimbun, on June 29, 2010)The research group is investigating a novel technology which integrates
Ultrasound and optical imaging (US/PAT), and a prototype model of the
Photoacoustic Mammography (PAM) has been introduced at the Clinical
Research Center for Medical Equipment Development. A clinical study of
PAM, which enables the visualization of neovascular networks of cancer,
has been started to demonstrate its usefulness in the early detection and
functional diagnosis of cancer without X-ray irradiation.
The ultimate goal of the project is to create a “healthy society” by promoting cutting-edge research and development, improv-ing quality of life (QOL) and reducing medical expenses for the aging society, while fostering talented researchers in an inter-disciplinary research area of medicine and engineering.
New Optical Coherence Tomography Equipment (OCT-HS100)
An Image of the Breast Cancer Examination with PAM
Innovative Techno-Hub for Integrated Medical Bio-Imaging
The Matching Program for Innovations in Future Drug Discovery and Medical Care
COE for Nano Quantum Information Electronics
Establishment of the Shionogi Inno-vation Center for Drug DiscoveryThe Shionogi Innovation Center for Drug Discovery was established in 2008 by Shionogi & Co., Ltd. as a profes-sional center of collaboration between industry and academia to nurture the seeds of technology sown by Hokkaido University and discov-er future drug discovery prospects. This 5-story center with a building area of 600 m2 and a floor area of 2,790 m2 is the first research facility from the private sector built within the grounds of a national university in Japan. Development of high-definition semiconductor PETThe clinical research system of Hokkaido University was en-hanced, and a total of about 680 clinical cases, which exceeded the number planned initially, were studied during the develop-ment of the high-definition semiconductor PET. The development framework has also been further enhanced through the devel-
Prototype models for semiconductor PET equipment and SPECT equipment used for brain
opment and introduction of a prototype semicon-ductor gamma camera in the Hokkaido University Hospital by Hitachi, Ltd., the commercialization of a radiation detector module, and other initiatives.Long-term human resources development for life sciencesEvery year, joint lectures for the Graduate Schools of Hokkaido University such as the “Shionogi Special Lecture on Drug Discov-ery Science,” the “Molecular Imaging Seminar,” and “Advanced Radiology, Nuclear Medicine, and Radiation Oncology” are conducted by more than 80 researchers from collaborating com-panies. This far, about 500 graduate students have attended the lectures in the last 5 years. A center for continued cooperation with the companies in developing such long-term manpower for the life science sector is also being formed.Advanced Radiation Therapy Project: Real-time Tumor-tracking with Molecular Imaging Technique Professor Hiroki Shirato proposed joint research on proton beam treatment to Hitachi, Ltd., and they have been developed many equipment. He was also the core researcher of the Funding Program for World-Leading Innovative R&D on Science and Tech-nology (FIRST program) in FY2009 under the title “Advanced Ra-diation Therapy Project: Real-time Tumor-tracking with Molecular Imaging Technique” selected by the Cabinet Office as one.
Posters advertising on the joint lectures conducted by the graduate school in FY2013
Advanced Interdisciplinary Center for the Establishment of Regenerative MedicineCOE for Nano Quantum Information Electronics
20 21
Cre
atio
n o
f Inn
ova
tion
Ce
nte
rs for A
dva
nc
ed
Inte
rdisc
iplin
ary R
ese
arc
h A
rea
s Prog
ram
22
Cre
atio
n o
f Inn
ova
tion
Ce
nte
rs for A
dva
nc
ed
Inte
rdisc
iplin
ary R
ese
arc
h A
rea
s Prog
ram
23
Osaka UniversityPhotonics Advanced Research Center
ORGANIZATION
Name Osaka University
U R L http://www.parcjp.org/
Address 2-1, Yamada-oka, Suita, Osaka TEL. 06-6879-7927 FAX. 06-4864-2695
Development of emerging industrial technologies in the 21st century from the fusion of photonics technology with nanotechnology and biotechnology
Overall Person-in-charge Toshio Hirano (President, Osaka University)
Researcher (Representative) Satoshi Kawata (Professor, Graduate School of Engineering)
Implementation Period FY2007 – F Y2016
Collaborating Organizations : Shimadzu Corporation, Sharp
Corporation, Nitto Denko Corporation, Mitsubishi Chemical
Group Science and Technology Research Center, Inc., IDEC
Corporation
■ 7th Year (FY2013)
Create prototyping models out of core technologies for inno-
vation such as bio-optical materials, optical control devices,
petabyte optical recording technologies, bioimaging/diagnosis
systems, and ubiquitous sensing systems, and evaluate the possi-
bility of industrializing them.
■ After Project Ends (around 2021)
Aim to create a research and development center for photonics
technology that is top of its class in the world. Build an unpar-
alleled industry-academia equal partner system that promotes
joint operations and R&D between Osaka University and industry
partners. And combine developmental phases in the commer-
cialization and industrialization process with output oriented
R&D starting from basic research in photonics. Innovations in
nanophotonics and plasmonics promoted through this center are
advanced themes in the whole photonics field that will serve as
a leading foundation for green and life innovations in the 21st
century and lead the world in science, technology and industry.
■ 10th Year (FY2016)
Aim to create and commercialize more than 20 products, among
developmental projects for commercialization and industrializa-
tion. Build an unprecedented interpenetrating partnership system
between industry and academia providing an interdisciplinary
environment in which people, technology, and space are joined
to form a melting pot for innovation. This system is expected to
churn out great numbers of personnel who excel industrializing
advanced science and technology and preeminent R&D achieve-
ments.
Collaboration System1
2 Overall Concept
Osaka University has established a new pho-
tonics research center to create photonics
innovations in collaboration with five indus-
try partners. Photonics is an interdisciplinary
academic domain that extends across a wide
range of fields such as physics, chemistry,
bioscience, materials science, electronics engi-
neering, and mechanical engineering. More-
over it is a base for cutting-edge technologies
such as nanotechnology, biotechnology, IT,
environmental technologies, and energy tech-
nologies.
As a global research center for photonics,
this center promotes interdisciplinary research
that cuts across academic barriers and scien-
tific societies ones through an interpenetrat-
ing partnership system that serves as a new
industry-academia collaboration model. We
develop PhD students who are leading pho-
tonics science and industry internationally.
RESEARCH THEME
2524
Osaka UniversityPhotonics Advanced Research Center
1 Eco Energy: Portable organic solar cells and highly sensible LEDs
Realize low-cost, long-life, light, and highly efficient or-
ganic thin film solar cells with organic semiconductors
that can be coated to form a film and proven to be ro-
bust and stable. Develop fluorescent materials to form
quantum dot to realize LED lighting technology that
saves energy and is also friendly to humans and the en-
vironment and contribute to improvements in safety and
security by counterfeit prevention technologies.
Social Value Bring about innovations in the eco en-
ergy field by commercializing portable emergency re-
sponse-type, independent, and decentralized energy
sources. Expedite the full replacement of conventional
lights with highly sensible LED lighting and ensure safety
and security in security applications.
Economic Value Secure a market for portable highly re-
liable, high-value-added solar cells. Ensure international
competitiveness using highly sensible, high-quality LEDs
and protect safe and high-quality commercial products
through counterfeit prevention technologies.
Expected Market Scale/Expected Achievement Period
Organic Solar cells: 12.8 billion yen in 2020; LED lights,
etc.: 5.5 trillion yen in 2020
Results to Date A conversion efficiency of 7% has been
attained for organic thin film solar cells and aiming to
produce larger devices. Elements with the world’s high-
est carrier mobility and energy conversion efficiency
higher than 3% have been
successfully developed in
coating-type, low molec-
ular, phthalocyanine solar
cells. Non-toxic semicon-
ductors quantum dot with
a high fluorescence quan-
tum yield that have been
developed at this center
has been applied to LEDs
and security.
Health & advanced medical devices: Biosensor, bio-imaging device, and nanospectroscopy mi-croscope
Develop multi-functional organic film biosensors for
managing human health, a new near-infrared fluorescent
probe (reagent) for the detection of enzyme activity that
will become a cornerstone of next-generation optical
diagnosis technology, a laser microscope for microscopic
observations of physiological phenomena in a live state,
and a nanometer microscope that allows DNA to be seen
using light.
Social Value Realize a healthy society that allows for
longevity through innovations in point-of-care systems,
early diagnosis, and devices for advanced medical/biolog-
ical research.
Economic Value Maintain an international lead and se-
cure international competitiveness for equipment and
products in the health and advanced medical device
fields.
Expected Market Scale/Expected Achievement Period
2.31 trillion yen in 2020
Results to Date Basic tests on the detection of markers
in lifestyle diseases such as hypertension, Alzheimer’s
disease, and diabetes have been carried out using mul-
tifunction organic film biosensors and product develop-
ment is ongoing. The image contrast of the microscopic
structure and spatial resolution of the laser microscope
for observing physiological phenomena have been im-
proved, and patents to establish the technologies to
commercialize the optical nanometer microscope have
been acquired. An enhanced cutting-edge Raman scat-
tering microscope has been made into a commercial
product. Gas chromatography with a markedly improved
sensitivity has also been developed as applied research
in plasma photonics, and this product is now being sold
worldwide.
Develop optically assisted magnetic recording technolo-
gies with plasmons optical enhancement at a metal tip
by two orders of magnitudes, and thin film magnetic
materials. Develop crystal for high-output ultraviolet la-
sers required for next-generation precision processing of
electronic devices and semiconductor processing.
Social Value Seize the international initiative in devel-
oping high density recording media that realizes a sub-
stantial improvement in saving energy used by IT devices.
Lead in manufacturing evaluation for next-generation
LSIs and precision processing of next-generation elec-
tronic devices.
Economic Value Ensure international competitiveness in
high density recording technologies. Maintain a global
share of the market for next-generation evaluation devic-
es for semiconductor manufacturing and manufacturing
equipment for precision electronic devices.
Expected Market Scale/Expected Achievement Period
High capacity optical storage: 26 trillion yen in 2020;
next-generation precision evaluation and processing
equipment: 2.7 trillion yen in 2020
Results to Date We developed thin film formation of
MnZn ferrite, a soft magnetic material that allows light
to pass through and is crucial magnetic head material for
optically assisted recording in next-generation magnetic
storage systems and analysed magnetization inversion
mechanism of the film. We have also successfully grown
the crystals for high-quality and high-power next-genera-
Collaborating Organizations : Mitsubishi Chemical Group Science and Technology Research Center, Inc., IDEC CORPORATION
Collaborating Organizations : Nitto Denko Corporation, SHIMADZU CORPORATION
tion ultraviolet lasers at a practical level and promoted to
commercialize it.
Collaborating Organizations : Sharp Corporation
Next-generation energy-saving, high-capacity optical storage and wavelength-conversion crys-tals for next-generation UV Laser for use in precise device- fabrication and semiconductor pro-cess-evaluation
2
3
Cre
atio
n o
f Inn
ova
tion
Ce
nte
rs for A
dva
nc
ed
Inte
rdisc
iplin
ary R
ese
arc
h A
rea
s Prog
ram
Cre
atio
n o
f Inn
ova
tion
Ce
nte
rs for A
dva
nc
ed
Inte
rdisc
iplin
ary R
ese
arc
h A
rea
s Prog
ram
26 27
The University of TokyoTranslational Systems Biology and Medicine Initiative
Development of minimally invasive, high-precision diagnosis and therapies through the fusion of integrated technologies in diagnosis and treatment with transformative technologies and antibody creation for cancer and lifestyle diseases
ORGANIZATION
Name The University of Tokyo
U R L http: //www.tsbmi.m.u-tokyo.ac.jp/index.html
Address 7-3-1, Hongo, Bunkyo-ku, Tokyo TEL. 03-5800-9079 FAX. 03-5800-9081 Overall Person-in-charge Junichi Hamada (President, the University of Tokyo)
Researcher (Representative) Takashi Kadowaki (Professor, Graduate School of Medicine)
Implementation Period FY2007 – FY2016
■ 7th Year (FY2013)
1 Begin independent, doctor-led clinical trials for minimally
invasive, high-precision diagnostic and treatment equipment
using labelled antibodies based on the pre-targeting of cancer.
Complete animal trials for diagnostic and treatment systems that
combine antibody drugs with an HIFU (High-Intensity Focused
Ultrasound ) endoscope system.
2 Obtain pharmaceutical approval and commence sales for ex-
panded indications of diagnostic drugs for Type 2 diabetes and
complete independent, doctor-led clinical trials for low molecular
drugs.
■ 10th Year (FY2016)
1 Begin clinical trials based on the Pharmaceutical Affairs Act
for minimally-invasive, high-precision diagnostic and treatment
equipment using labelled antibodies based on the pre-targeting
of cancer. Enter into clinical trials based on the Pharmaceutical
Affairs Act for diagnostic and treatment systems that combine
antibody drugs with an HIFU (High-Intensity Focused Ultrasound)
endoscope system.2 Enter into independent, doctor-led clinical trials for antibody
drugs and clinical trials based on the Pharmaceutical Affairs Act
for low molecular drugs for Type 2 diabetes.
Collaboration System1
2 Overall Concept
This research aims at the
development of local-
ized treatment devices
and cell-specific drugs
against diseases in the
human body, as opposed to traditional inva-
sive medical devices and non-selective drugs
with many side effects. It is also a goal to
build a development center to provide safe,
secure, and compassionate medical treat-
ment. For these purposes, we will make use
of the features of the different missions that
companies shoulder in clinical research (pa-
tient specimens, access to information), basic
research (ability to obtain genes, cells, etc.;
theoretical and system operation capability)
and commercialization (ability to provide
funds for clinical trials and commercialization
technologies, etc.). We will break down the
traditional barriers inherent in one-to-one
joint research between universities and corpo-
rations and establish a new industry-academia
partnership system to advance research and
development in a cyclic manner from “clinical
to basic to commercialization to clinical.” This
will be achieved with the university acting as
platform for interdisciplinary research by the
university’s various laboratories, which possess
basic core technologies and information, and
numerous companies possessing world-lead-
ing elementary core technologies.
Collaborating Organizations : Forerunner Pharma Research
Co., Ltd., Olympus Corporation, Sekisui Medical Co., Ltd.,
Toray Industries Inc., Mitsubishi Tanabe Pharma Corporation,
Hitachi Aloka Medical, Ltd., Nikon Corporation, Kowa Compa-
ny, Ltd.
■ After Project Ends (around 2019)
In addition to systematically and comprehensively identifying
cell-specific target proteins in cancer and lifestyle focal lesions
based on system disease life science, combine imaging using an
artificial protein probe with less invasive high-precision medical
device to integrate diagnosis and treatment at a low cost and
commercialize innovative drugs and treatment systems with few
side effects.
RESEARCH THEME
2928
The University of TokyoTranslational Systems Biology and Medicine Initiative
1 Development of advanced medical technologies for treating cancer: Shortening treatment time
Besides labelling and creating antibodies against target
proteins from cancer cells and developing imaging tech-
nology that concentrates antibodies specifically at cancer
cells, integrate high-precision, less invasive diagnostic
and treatment methods for cancers with extremely high
specificity by developing an HIFU (High Intensity Focused
Ultrasound) endoscope using target antibodies.
Social Value Earlier cancer treatment becomes possible.
This will result in a drastic shortening in the treatment
time, while treatment methods that are less invasive will
allow treatment to be carried out on elder patients with
reduced physical strength, thereby substantially improv-
ing the QOL of patients in an ageing society.
Economic Value Through the use of endoscopic treat-
ment and less invasive, high-precision cancer treatment
technologies, treatment time is reduced by two-thirds or
more, making outpatient treatment possible. This will in
turn contribute to a large containment of medical costs.
Expected Market Scale/Expected Achievement Period
The total market scale in 2025 (8 years after end of im-
plementation period) for diagnostic and treatment equip-
ment and treatment drugs is assumed as follows.
● Diagnostic and treatment equipment: Japanese mar-
ket : 7 billion yen ; global market: 90 million dollars
● Treatment drug: Japanese market: 30 billion yen;
global market: 1.95 billion dollars
Results to Date In the development of new treatments
for colorectal cancer using antibody drugs and HIFU (high
intensity ultrasound) endoscopes, antibodies for specific
cancer antigens (CCA1) found at this center have been
successfully created and used in humans. Furthermore,
technology to adorn phase-changing nano-droplets (re-
versible bubbling between the gas and liquid states using
ultrasound waves) in human antibodies has also been
developed. By combining such antibodies adorned with
phase-changing nano-droplets with the HIFU endoscope
developed at this center, it is possible to integrate less
invasive ultrasound diagnosis with pinpoint cancer treat-
ment through the creation of micro-bubbles (for killing
cancer cells) using ultrasonic irradiation and high-preci-
sion image diagnosis of deep areas in the body.
Development of advanced medical technologies for the treatment of lifestyle diseases : Con-trolling medical expenses for treating lifestyle diseases
Besides developing imaging technology for blood vessel
and arteriosclerosis diagnosis and the quantitative meas-
urement of visceral fats using less invasive, high-preci-
sion diagnostic and treatment device, drugs for the early
diagnosis and treatment of cancers using antibodies and
low molecular compounds against target proteins are
also being developed. Furthermore, fusion medical tech-
nologies created by optimizing a combination of these
two technologies are being developed as well.
Social Value Safe and secure diagnostic and treatment
technologies can be developed and supplied by decreas-
ing the economic burden and reducing disease complica-
tions through early diagnosis, thereby helping to reduce
the physical burden of patients in an ageing society.
Economic Value A 30% reduction in medical expenses
for treating lifestyle diseases can be realized.
Expected Market Scale/Expected Achievement Period
The total market scale in 2025 (8 years after end of im-
plementation period) for diagnostic and treatment device
and treatment drugs is assumed as follows.
● Diagnostic device: Japanese market: 13.7 billion yen;
global market: 0.78 billion dollars
● Treatment drug: Japanese market: 10.5 billion yen;
global market: 1.06 billion dollars
Results to Date In the development of less invasive and
early diagnostic methods for metabolic syndromes (MS),
a system for measuring adiponectin with a high molecu-
lar weight, which is a key molecule in diabetes and MS,
has been developed. An early diagnostic method for MS
has been established and proven to be effective in the
early diagnosis of cardiovascular complications. By using
this as a companion diagnostic drug in personalized and
tailor-made medical applications, subject patients for ad-
iponectin receptor activators can be identified. Further-
more, quantitative measurement technology using less
invasive, high-precision abdominal ultrasound that over-
comes the shortcomings in the traditional quantitative
measurement of visceral fats has also been developed.
Accelerate “exit-oriented R&D” that aims to industrialize and commercialize products at an early stage and further cre-
ate new innovations in the development of novel, less invasive drugs and medical devices with fewer side effects and
lower costs in collaboration with eight participating companies.
Collaborating Organizations : Forerunner Pharma Research Co., Ltd., Kowa Company, Ltd., Olympus Corporation, Hitachi Aloka Medical, Ltd.Collaborating Organizations : Mitsubishi Tanabe Pharma Corporation, Toray Industries Inc., Sekisui Medical Co., Ltd., Hitachi Aloka Medical, Ltd., Nikon Corporation, Kowa Company, Ltd.
2
30
Cre
atio
n o
f Inn
ova
tion
Ce
nte
rs for A
dva
nc
ed
Inte
rdisc
iplin
ary R
ese
arc
h A
rea
s Prog
ram
31
Tohoku UniversityR&D Center of Excellence for Microsystem Integration Research Initiative
ORGANIZATION
Name Tohoku University
U R L http://www.rdceim.tohoku.ac.jp/
Address 2-1-2, Katahira, Aoba-ku, Sendai-shi, Miyagi Prefecture TEL.022-717-7800 FAX. 022-229-4115
Development of micro-system hetero-integration technology using a combination of MEMS technology and LSI technology
Overall Person-in-charge Susumu Satomi (President, Tohoku University)
Researcher (Representative) Takahito Ono (Professor, Graduate School of Engineering)
Implementation Period FY2007 – FY2016
Collaborating Organizations : Ricoh Company, Ltd., Top-
pan Technical Design Center Co., Ltd., Mems Core Co., Ltd.,
Kitagawa Iron Works Co., Ltd., Sumitomo Precision Products
Co., Ltd., Toyota Motor Corporation, The Nippon Signal Co.,
Ltd., Nidec Copal Electronics Corporation, Nihon Dempa Kogyo
Co., Ltd., Pioneer Corporation, MEMSAS Inc., Toyota Central
R&D Labs., INC., NIKKO Company, Japan Aviation Electronics
Industry, Ltd., Furukawa Electric Co., Ltd., Denso Corporation
■ 7th Year (FY2013)
1 Equip the established R&D center with shared facilities and
build up infrastructure, intellectual property, and Shared wafer
R&D systems.
2 Resolve various R&D issues related to the processing, equip-
ping, and installation of micro-systems that combine LSI and
MEMS technologies and establish the basic technologies required
for interdisciplinary research. Verify the functions of several com-
bined micro-systems and obtain an outlook for commercializa-
tion purposes.
■ After Project Ends (around 2018)
1 Autonomously maintain a venue that supplies the best tech-
nologies, manpower, information, and opportunities at the most
suitable time and cost to society through private investment as
well as national and local investments.
2 Build a research center in which the R&D regarding combined
micro-systems and application products that are globally com-
petitive can be quickly carried out in an integrated fashion, from
design and elementary research to prototyping and commercial-
ization.
■ 10th Year (FY2016)
1 Continuously lead new technological development as an es-
tablished R&D center while partnering with various companies,
research institutions, and administrative bodies. Contribute to
the international competitiveness of relevant industries through
R&D related to micro-systems for future applications.
2 Supply developed interdisciplinary technologies for the com-
mercialization of products that are competitive in the market in
a variety of fields.
Collaboration System1
2 Overall Concept
Develop advanced micro-systems to support
a safe, secure, and wholesome social system
by combining cutting-edge LSI technologies
and MEMS technologies to create a paradigm
shift (“More than Moore”) that is sought
through LSI miniaturization. For that purpose,
R&D will be carried out among five research
groups (refer to the figure on the collabora-
tion system). Build a research center that will
generate strong industrial competitiveness
internationally by using the knowledge of
the university as a catalyst for industry-indus-
try-academia partnership, and by building an
open venue that is furnished with the nec-
essary reforms in infrastructure, intellectual
property (patent basket), and R&D systems
(Shared wafer system) to allow R&D to be
carried out jointly among multiple companies
and research institutions. Manpower devel-
opment to support this research center is also
being implemented by sending researchers to
overseas research institutions such as IMEC
based on a strategic partnership agreement
(the first in Asia), and by conducting intensive
courses and learning programs on MEMS that
are targeted at working adults.
Junichi Nishizawa Memorial Research Center
MEMS prototyping line
RESEARCH THEME
33
3 Golay cell-type integrated infrared sensor array
Infrared linear sensors for spectral measurement purpos-
es (e.g. environmental monitoring of greenhouse gases
and emission gases, monitoring of environmental con-
ditions in plant factories, safety monitoring in factories)
are being developed. Golay cell-type infrared sensors
that are sensitive in a wide range of wavelengths have
been integrated by being bonded onto an LSI made with
Shared wafer system.
Social Value In recent years, the need for an environ-
mentally-ubiquitous wireless sensor network to realize a
safe, secure, and clean society has heightened. Infrared
sensing is a means of environmental sensing. This sensor
is able to perform non-destructive measurements and
has the added advantage of being safe and not impact-
ing the human body at all.
Economic Value Use is possible in a wide range of appli-
cations, such as environmental conservation, security,
and consumer devices, and thus the economic value is
extremely high.
Expected Market Scale/Expected Achievement Period
The global market for ultra-sensitive infrared detector
elements is expected to reach 260 million dollars in 2017
and 460 million dollars in 2023. Collaborating company
aims to enter the market in 2017.
Results to Date A Golay cell has been successfully min-
iaturized and made into an array using microprocessing
technologies. the infrared sensor array (Golay cell array)
mounted on top of an LSI designed and made with
Shared wafer system has been produced, and it has
demonstrated the ability to measure infrared radiation
with high sensitivity.
32
Tohoku UniversityR&D Center of Excellence for Microsystem Integration Research Initiative
1 Development of tactile sensors for robots
A full-body tactile sensor network system using MEMS-
LSI integrated devices for a life support robot has com-
bined characteristics such as low-power consumption,
small size, little wiring, interrupt communication, and
high-speed, high-precision sensing. Integration and
packaging of dedicated LSIs by our shared wafer system
and MEMS force sensors, that is a way to allow above
features, are being developed.
Social Value We aim to develop a robot that can safely,
securely, and pleasantly support human activities from
the sidelines, such as by keeping a watch over human
activities, or through gentle interactions with humans.
Economic Value Anthropomorphic robots (an area in
which Japan has an edge) are expected to spread through-
out Japan and the world. Instead of replacing the current
market, a significant feature of the technology lies in the
fact that a whole new market may be opened up.
Expected Market Scale/Expected Achievement Period
The global market for life support robots is expected to
start from a scale of 100 million dollars per year in 2017
at the point of launch and then exceed 80 billion dollars
per year in 2031.
Results to Date A tactile sensor network system using
generic parts such as existing sensors and dedicated LSIs
with integrated MEMS force sensors on top has been
completed, and overall development of a system using
integrated devices is ongoing. An Outstanding Paper
Award was also given out at Transducer 2011, one of
the world’s most foremost international conferences in
the field.
2 Development of an integrated micro-biosensor system
We are developing a bioimaging and simultaneous multi-
ple analysis system applied in wide fields including med-
icine, environmental monitoring, and food industry. The
“Bio-LSI” is our current detection-type biosensing sys-
tem, which successfully carried out unprecedented high-
speed, high-sensitivity measurements.
Social Value Our unprecedented sensing technologies
potentially provide systems to guarantee safety and se-
curity in the medical, environmental, and food industries,
as well as platforms for replacements for animal tests in
pharmaceutical development, technologies to screen for
useful molecules in the engineering field, and tools for
investigating biological functions in the life science.
Economic Value Our research has significant economic
effect to provide a technology for safety and security in
the modern world, which is rapidly ageing and facing se-
rious environmental, health, and safety problems.
Collaborating Organizations : Toyota Motor Corporation, Toyota Central R&D Labs.,INC.
Collaborating Organizations : Sumitomo Precision Products Co., Ltd.
Collaborating Organizations : Toppan Technical Design Center Co., Ltd., Japan Aviation Electronics Industry, Ltd.
Expected Market Scale/Expected Achievement Period
The global market for array-type micro-biochips for DNA
and protein detection is expected to reach 9.6 billion dol-
lars in 2016 and 18 billion dollars in 2020 and this center
aims to enter the market in 2017 at the end of the pro-
gram.
Results to Date We have developed a practical system
that can take current measurements at a high speed (18-
125 ms/400 point) and a wide range with high sensitivity
(from ±1 pA to ±100 pA). We successfully got images
showing activities of bio-molecules such as enzymes and
cell division markers with high sensitivity. Figure shows
the results of the real-time imaging for diffusion of hista-
mine.
34
Cre
atio
n o
f Inn
ova
tion
Ce
nte
rs for A
dva
nc
ed
Inte
rdisc
iplin
ary R
ese
arc
h A
rea
s Prog
ram
35
Kyushu UniversityInnovation Center for Medical Redox Navigation
Combine the wisdom of the Kyushu University with the creativity of different industries to create an advanced interdisciplinary medical research areas
ORGANIZATION
Name Kyushu University
U R L http://redoxnavi.kyushu-u.ac.jp/english/
Address 3-1-1, Maidashi, Higashi-ku, Fukuoka-shi, Fukuoka Prefecture TEL. 092-642-6031 FAX. 092-642-6024Overall Person-in-charge Setsuo Arikawa (President, Kyushu University)
Researcher (Representative) Yoshiki Katayama (Professor, Graduate School of Engineering, Kyushu University)
Implementation Period FY2007 – FY2016
Collaborating Organizations : JEOL Ltd., Shimadzu Corpo-
ration, Mitsubishi Tanabe Pharma Corporation, Taiho Pharma-
ceutical Co., Ltd., HOYA Corporation, Fuji Electric Co., Ltd.,
NOF Corporation, Kyushu Electric Power Co., Inc.
■ 7th Year (FY2013)
1 Verify the usefulness of endogenous molecular probe and clin-
ically relevant redox measurement technologies. Carry out a study
on the effectiveness of the system towards realizing minimally
invasive treatments using redox navigation system. Implement
improvements towards large-scale verification tests starting from
small-scale verification tests in the health support system.2 Study effectiveness for preventing the onset of and complica-
tions arising from diabetes, verify the usefulness of bio-markers for
predicting the effects of anti-cancer drugs, perform toxicity tests
of polymeric micelles on large animals, and carry out drug effect/
drug mechanism studies. Search for prognosis marker, clinical test
applicability of mass spectrometry.
■ 10th Year (FY2016)
1 Complete the development of clinically relevant redox imag-
ing system and apply it to pre-clinical trials. Produce a compact
surgery support system capable of working within the gantry of
an Overhauser effect MRI (ReMI) and combine it with a variety of
treatment systems. Carry out verification research through an ex-
tensive network.2 Establish the clinical usefulness of a new measurement system
for oxidative stress markers. Implement Phase II and Phase III clini-
cal trials for gene therapy including polymeric micelles. Complete
the development of a mass spectrometer for cytological diagnosis
and expand the market for mass spectrometry to clinical sites.
Collaboration System1
2 Overall Concept
This center aims to create an advanced in-
terdisciplinary medical research area for the
development of medicines and establishment
of early diagnosis and treatment methods for
redox-related diseases such as lifestyle-related
diseases, cancer, and neurological disorders.
The center adopts the common concept of
changes in the oxidation-reduction phenom-
enon in the human body (redox) as a possible
cause and exacerbation of various diseases.
The center advocates the concept of “redox
navigation,” which will lead to the diagnosis
and treatment of such diseases by measuring
and visualizing in vivo redox, and investigat-
ing affected area and disease mechanisms.
In order to achieve these aims, the collective
wisdom of Kyushu University in the medical,
pharmacological, agricultural, and engineer-
ing fields will be collated together with the
creative powers of various industries in the
medical, pharmaceutical, and analytical in-
struments fields. In addition, it will promote
industry-academia and industry-academia-in-
dustry partnerships through interdisciplinary
research among the group members and
cultivate human resources to drive the “bio-
redox navigation” research area.
■ After Project Ends (around 2021)
1 This center will be taken over by the Incubation Center for Ad-
vanced Medical Science (ICAMS), where a variety of companies
and research institutions will gather to conduct advanced research
mainly on redox navigation in collaboration among the participat-
ing companies. A center of excellence where technologies can be
commercialized in a beneficial manner will be established.2 Develop outstanding young investigators through collaborative
research in the advanced interdisciplinary medical field and con-
tribute to the development of university research and corporate
research and business activity.
RESEARCH THEME
37
3 Creating the seeds for drugs to prevent the onset of diabetes and to treat diabetes complications
Use bio-redox analysis and diagnostic technology to
establish an integrated technology foundation for the
development of drugs and treatments to control the on-
set of and complications arising from diabetes. Sow the
seeds that will contribute to the clinical development of
drugs for clinical applications based on this technology.
Social Value Improve the QOL of diabetic patients by
searching for new drug discovery seeds that will help to con-
36
Kyushu UniversityInnovation Center for Medical Redox Navigation
1 Production of clinically conforming redox scanner
An Overhauser enhanced MRI (OMRI/ReMI) is an indirect
free-radical imaging system that is useful for measuring
in vivo redox. Therefore a high-sensitivity ReMI will be
developed for clinical applications. In addition, three el-
ementary technologies—a redox endoscope, a compact
surgery support system, and an image guided system—
will be developed and integrated to build a in vivo redox
surgery support system.
Social Value The number of patients and people at risk
of lifestyle-related diseases exceeds 10 million in Japan.
The discovery rate for superficial cancer in the gastroin-
testinal tract, etc. will be improved.
Economic Value Create a new market for new measure-
ment instruments. Drastically reduce the physical and
economic burden of patients.
Expected Market Scale/Expected Achievement Period
Over 1 billion yen/5 years after end of implementation
period
Results to Date A clinically relevant prototype ReMI has
been produced. A ReMI receiver coil that can be inserted
into the forceps opening of an endoscope has been de-
veloped.
Collaborating Organizations : JEOL Ltd., Fuji Electric Co., Ltd., HOYA Corporation
Collaborating Organizations : Mitsubishi Tanabe Pharma Corporation
2 Establishment of pathological metabolomics using mass spectrometry for cytological diagnosis
Apply the Matrix-Assisted Laser Desorption/Ionization
(MALDI) method in the measurement of metabolites and
carry out technological development to achieve rapid
analysis for the establishment of a new domain in patho-
logical metabolomics based on a mass spectrometer sys-
tem for drug discovery research.
Social Value Enable pathological diagnosis to be carried
out rapidly using mass spectrometry.
Economic Value Stimulate the market for mass spectrom-
eter systems for cytological diagnosis that can be used at
clinical sites.
Expected Market Scale/Expected Achievement Period
The market for mass spectrometry equipment used in
the analysis of related bio-molecules is expected to reach
27.5 billion yen 5 years after the end of the implementa-
tion period.
Results to Date In order to expand the market to cover
clinical sites, matrix development and software develop-
ment to turn the equipment into a general-purpose mass
spectrometry
s y s t e m f o r
cytological di-
agnosis have
been carried
out.
Collaborating Organizations : Shimadzu Corporation
5 Development of anti-cancer agent and gene therapy carrier
A search for target molecules that will serve as the weak
points of the cancer cells and enhancement of the an-
ti-cancer effect is being carried out based on the action
mechanisms of existing anti-cancer agents. Development
of genetic treatment drugs containing polymeric micelles
for cancers that are hard to treat is also ongoing.
Social Value Develop a market and innovations in the
field of anti-cancer agents, DDS, and drug discovery.
Economic Value The economic value is expected to reach
several hundred billions of dollars if new drugs and treat-
ment methods targeting cancer are developed.
Expected Market Scale/Expected Achievement Period
The market launch timing and revenue forecast is pend-
ing, s ince these wil l
differ according to the
t ype o f cance r and
stage.
Results to Date A study
on the examination method for predicting the effects
of cancer chemotherapy using redox imaging and me-
tabolomics is being conducted. Production of carriers to
introduce polymeric micelle genes has been carried out
at the experimental level, and GMP manufacturing devel-
opment has also been completed.
Development of a confocal endoscope using MEMS tech-
nology that was started as an interdisciplinary research
project by HOYA, Fuji Electric, and Kyushu University,
and a hyper spectral camera whose development was
started in consideration of clinical needs.
Social Value Minimally invasive treatment can be real-
ized with a surgery support system that includes redox
imaging.
Economic Value Reduce the physical and economic bur-
den on patients.
Expected Market Scale/Expected Achievement Period
Over 1 billion yen/5 years after end of implementation
period
Results to Date Software development has been com-
pleted and collaboration with the Center for Advanced
Medical Innovation will be carried out for clinical re-
search. In addition, agreements have been concluded in
various Asian coun-
t r i e s to exped i te
the approval of the
medical device, and
verification tests will
also be conducted
overseas.
Collaborating Organizations : HOYA Corporation, Fuji Electric Co., Ltd.
4 Development of a redox endoscope
trol the onset of and complications arising from diabetes.
Economic Value Contribute to the development of drugs and
early treatment methods for lifestyle diseases (5–6 trillion yen)
Expected Market Scale/Expected Achievement Period
Overall medical costs for lifestyle diseases are expected to
amount to several trillion yen. The timing for the market
launch is still pending, as these are still seed technologies
for drug discovery.
Results to Date Evidence demonstrating the ability to
suppress the progress of diabetic vascular complications
through anti-oxidation has been verified for the first time
ever. Based on treatment via a potential target, oxida-
tive stress improvements and kidney improvements have
been demonstrated for a diabetes model.
Collaborating Organizations : Taiho Pharmaceutical Co., Ltd., NOF Corporation
Mixed polymer
38
Cre
atio
n o
f Inn
ova
tion
Ce
nte
rs for A
dva
nc
ed
Inte
rdisc
iplin
ary R
ese
arc
h A
rea
s Prog
ram
39
ORGANIZATION
Name Kyoto University
U R L http: //www.ak.med.kyoto-u.ac.jp/
Address Yoshida Konoe-cho, Sakyo-ku, Kyoto-shi, Kyoto TEL. 075-753-9501 FAX. 075-753-9500
Collaboration System1
2 Overall Concept
Kyoto UniversityCenter for Innovation in Immunoregulatory Technology and Therapeutics (AK project)
Overall Person-in-charge Hiroshi Matsumoto (President, Kyoto University)
Researcher (Representative) Shuh Narumiya (Professor, Graduate School of Medicine)
Implementation Period FY2007 – FY2016
Collaborating Organizations : Astellas Pharma Inc.
■ By 7th Year (FY2013)
1 Identify and examine at least 25 target molecules. Use spec-
imens from patients to examine clinical relevance of the pro-
posed targets for differentiation from existing drugs to create
game-changing drugs. Proceed the targets on which we can
build the drug discovery concept to the Drug Discovery Program
of Astellas Pharma in which optimization of compounds and an-
tibodies are carried.
2 Develop humanized mice, iPS cell applications, bio-imaging
and simulation of the immune system, and the system and tech-
nology for clinical specimen analysis to search bio-marker and
improve the predictability in the pre-clinical stage so as to in-
crease the success rate in clinical trials.
■ After Project Ends (around 2021)
1 Launch more than three drugs onto the market with indica-
tions in diseases such as rheumatoid arthritis, systemic lupus ery-
thematosus and allergy and as immunosuppressant.
2 Based on the AK project model, will establish a drug R&D
center at Kyoto University, which continues to support industry-
academia collaboration and enhance international competitive-
ness of drug industry in Japan.
■ By 10th Year (FY2016)
1 Will complete evaluation of efficacy and safety of candidate
compounds, biologics and new medical technology in pre-clini-
cal test and will create more than three drugs to launch. Phase I
clinical trials on drug candidates ready by this time will be started
either by the company or at the Translational Research Center of
Kyoto University.
2 Will produce more than 20 medical scientists and other tal-
ents specialized in drug discovery as senior researchers and ten-
ured staffs in universities, companies, government agencies, and
other organizations.
The purposes of the AK project are i) devel-
opment of “next-generation immunoregula-
tory medicines” by combining drug discovery
technologies of Astellas Pharma and basic
and clinical research in Kyoto University Grad-
uate School of Medicine and Kyoto University
Hospital, ii) creating a model of industry-
academia collaboration for drug discovery in
the post-genome era, and iii) nurturing sci-
entists and other talents specialized in drug
discovery. Specifically, we have established
the Fusion labolatory in the campus of Kyo-
to University Graduate School of Medicine,
where researchers from Graduate School of
Medicine of Kyoto University work togeth-
er with researchers from Astellas Pharma in
order to carry out interdisciplinary research
and establish an efficient drug discovery R&D
system. Through these efforts, we aim to de-
velop innovative drugs in immunology area
to fulfill unmet medical needs in intractable
diseases such as allergies, autoimmune dis-
eases, chronic inflammatory diseases, chronic
infectious diseases, organ transplantation and
cancer. By such accomplishment, we will con-
tribute to the health and welfare of human
beings, and strengthen the international com-
petitiveness of the pharmaceutical industry in
Japan. Furthermore, we nurture and produce
scientists and other talents specialized in drug
discovery, who possess integral knowledge
and skills in medicine, drug discovery, intel-
lectual property and other related fields, and
who function as the interface between indus-
try and academia to promote drug discovery
in future.
Developping “Next-generation immunoregulatory therapeutics” by combining drug discovery technologies of Astellas Pharma and medical research of Kyoto University
RESEARCH THEME
41
3 Discovery of new drugs for atopic dermatitis
Keratinocytes in the skin
ep i the l ium funct ion as
a barrier against foreign
substances. In atopic der-
matitis, this keratinocyte
barrier is impaired because
o f down- regu la t ion o f
expression of filaggrin, a
cross-linker of keratin and a source of natural moisture
substances. At this project, we collaborate with De-
partment of Dermatology, Kyoto University Hospital, to
create an innovative drug that is capable of restoring im-
paired skin barrier in atopic dermatitis patients by upreg-
ulaiton of filaggrin expression and therefore differs from
steroids traditionally used in this disease.
Social Value Improve QOL of patients.
Economic Value As an orally active drug, substitute for
steroid ointment and make a new market.
Expected Market Scale/Expected Achievement Period
106.8 billion yen/year (Japan, the U.S., Europe); expected
launch in 2027, 11 years after the end of the implemen-
tation project
Results to Date Obtained a tool compound that upreg-
ulates the filaggrin expression in cultured skin cells and
shows improvement of the conditions in a mouse model
of atopic dermatitis. Large-scale compound exploration
on the target molecule of this compound is being imple-
mented.
40
Kyoto UniversityCenter for Innovation in Immunoregulatory Technology and Therapeutics (AK project)
1 Discovery of new drugs for rheumatoid arthritis (RA)
Rheumatoid arthritis (RA) is a disease of inflammation
of the synovial membrane in the joint, causing swelling,
continuous inflammation, pain, and deformation of af-
fected joints. While introduciton of anti-TNF therapy has
significantly improved its treatment, the effectiveness
and remission rate are still insufficient, and infection
caused by immunosuppression also occurs. At this pro-
ject, we therefore extract information thorugh analysis
of patient samples and create a novel type of drugs that
work directly on synovial membrane to suppress inflam-
mation and prevent joint damage.
Social Value Improvement in QOL of RA patients and
loss of the social labour force due to this disease by
achievement of higher remission rate in RA patients
including those unresponsive to existing drugs (such as
anti-TNF drugs).
Economic Value Reduction in costs for treating RA pa-
tients by decreasing the number of surgeries for synovial
membrane removal and joint replacement for patients
unresponsive to existing drugs as well as avoiding infec-
tions accompanying existing drugs, and by increasing
the proportion of patients with remission and drug-free
maintenace.
Expected Market Scale/Expected Achievement Period
268.7 billion yen/year (Japan, the U.S., and Europe);
expected launch in 2026, 10 years after the end of the
project
Results to Date Identified a target molecule by analysis
on synovial membrane tissue of RA patients, the anti-
body against which suppresses thickening of human syn-
oviocytes and shows high effectiveness in animal model
of the disease. Various lines of studies are being carried
out to develop this antibody as a clinical medicine.
2 Discovery of new drugs for systemic lupus erythematosus (SLE)
SLE is triggered by deposition of immunocomplex of cell
components and their auto-antibodies in the tissues such
as kidney, skin and brain, which eventually causes injury
of these tissues by inducing lymphocyte attack. SLE is
frequent in pubescent and post-pubescent females. The
etiology of SLE is not yet known, and symptoms differ
from patient to patient. At this project, we combine
analysis of its pathogenesis by basic immunology, analy-
sis of patient specimens with clinicians for validation and
patient stratification, and analysis of therapeutic efficacy
of antibodies created by Astellas Pharma in animal mod-
els to develop new treatment for this intractable disease.
Social Value Due to its superior therapeutic effect and
excellent safety, the drug can substitute for current drugs
including cyclophospha-
mide and MMF and be
expected to administer
sa fe l y to women o f
fertile capacity, thus ex-
panding the number of
applicable patients.
Economic Value Drastic
reduction in the cost for
SLE patients by reducing
the dose of steroid, which is not possible with existing
drugs, and preventing its adverse effects such as bone
fracture, infection, hypertension, and hyperlipidemia.
Collaborating Organizations : Astellas Pharma Inc.
Collaborating Organizations : Astellas Pharma Inc.
Expected Market Scale/Expected Achievement Period
105.8 billion yen/year (Japan, the U.S., Europe); expected
launch in 2027, 11 years after the end of the project.
Results to Date Identified a new drug target and mecha-
nism that may cause kidney injury and facilitate autoanti-
body production from the findings of basic immunology
research. An antibody against this molecule improved the
pathology in an SLE animal model. Creation of a human
antibody is in progress.
Collaborating Organizations : Astellas Pharma Inc.
4342
06
In-Depth Focus 06
In-Depth Focus 05 Osaka University
05
Tohoku University
07
In-Depth Focus 07
The University of Tokyo 東 京大 学The University of Tokyo
The keyword for emerging industrial technology in this 21st century is photonics. Osaka University’s Photonics Advanced Re-search Center aims to innovate science and industries by combining photonics, nanotechnology and biotechnology.
Together with Shimadzu Corporation, one of the member companies, this project pursued applied research on plas-ma photonics to develop the gas chromatograph Tracera, which features significantly enhanced detection sensitivity and is now marketed throughout the world by Shimadzu Corporation. The system is also capable of handling more samples than those with conventional detection methods.
Commercialization of tip-enhanced Raman scattering nanomicroscope
Productization of a new high sensitive gas chromato-graph system
Photonics Advanced Research Center Photonics (Science and Technology of light)
Kyushu University
08
Prototype of portable ReMI equipment with magnetic circuit
In-Depth Focus 08
Innovation Center for Medical Redox Navigation
towards the development of drugs and the establishment
of early diagnosis and treatment methods for redox-re-
lated diseases. Thus far, development of redox measuring
technology using the Overhauser effect has been carried
out, and a new type of MRI equipment (ReMI) in which
the magnetic circuit moves precisely has been developed.
This equipment allows the disease mechanism to be un-
derstood and visualized, and this is further expected to
lead to a new kind of medical diagnosis technology and
drug efficacy image analysis in drug development, includ-
ing with regard to anti-oxidation drugs.
Kyushu University Hospital, west wing “Innovation Center for Medical Redox Navigation”
R&D Center of Excellence for Microsystem Integration Research InitiativeDevelopment of integrated micro-biosensor system (through industry-industry-academia collaboration)
Jun 2, 2012 Nikkan Kogyo Shimbun
Manufactured bio-LSI measurement system (the LSI in the newspaper article photo is built-in)
Tohoku UniversityBio-sensing research based on electrochemical reaction using a 2D array LSI
Roles in industry - industry - academia collaboration
Development of device package and measurement system
Japan Aviation Electronics Industry
ToppanLSI design and creation using shared wafer sysytem
In recent years, excessive free radicals have been pro-
duced due to various changes in environmental factors
and unhealthy lifestyle, resulting in a breakdown of the
redox balance. As a result, the possibility that cancer,
lifestyle diseases, heart diseases, and the like may arise
has been pointed out. For example, 60% of the deaths
in Japan are said to be related to lifestyle diseases, and
thus the creation of advanced interdisciplinary medicine
focusing on redox is thought to be a national priority.
In this research center, researchers in medicine, phar-
macological, agriculture,
and engineering gather at
dedicated laboratories (about
2,000 m2) on the 5th and
6th floors of the west wing
within the university hospital
campus to carry out research
with the aim of creating ad-
vanced interdisciplinary med-
ical research areas oriented
The project succeeded in product development of tip-en-hanced Raman scattering microscope that utilizes light intensity enhancement by plasmon resonance at nano-meter scale. The product is now to be sold from a startup company. The technology has been under basic research for 20 years. The manufacturing of sharp nano-structured metal probes is one of the key technologies.
The system is made up of 20x20 current detection arrays, ampli-fication electrodes and LSI on top of which liquid reservoirs (with liquid specimens inside) are constructed. By capturing the chang-es in the current due to the electrochemical reaction that occurs in liquid specimens such as an enzyme in the reservoirs, DNA, bio-molecules, etc., the analysis of the behaviour and identifica-tion of type can be carried out in real time.
Translational Systems Biology and Medicine Initiative
【Participating in national politics】Advisor to the Office of Healthcare Policy un-der the Cabinet Secretariat: Yoichiro Matsumoto (Vice President, The University of Tokyo; Professor, School of Engineering)
Deputy Center Director (for Medical Devices), Phar-maceuticals and Medical Devices Agency (PMDA) : Ichiro Sakuma (Deputy Head of Research Center)
In an ageing society such as Japan where the number of deaths is increas-ing rapidly, the main causes of death are cancer, stroke, and heart diseas-es caused by lifestyle diseases. Treatments are invasive, with significant side effects, and the financial situation is dire due to high medical costs. In addition to systematically and comprehensively identifying cell-specific target proteins in cancer and lifestyle focal lesions based on translational systems biology and medicine, this center also aims to commercialize in-novative drugs and medical devices at a low cost and with few side effects by combining both diagnosis and treatment and by fusing less invasive, high-precision medical devices with imaging using an artificial protein probe together with collaborating organizations. The head of the research center, Professor Takashi Kadowaki, is a preeminent scholar in diabetes research who has achieved significant results and made numerous contri-butions over many years in the medical world. In 2010, 2011, and 2013, he was awarded the Purple Ribbon Medal, the Takeda Medical Science Prize, and the Japan Academy Award, respectively.
In the development and analysis of bio-marker measurement technology using clinical specimens, the development of the LCMS-8050 mass spectrometer, which provides sensitivity that is 10 times higher than that of existing models, has been successfully completed ahead of schedule, and sales were launched by Shimadzu Corporation on Aug 22, 2013. Furthermore, using this device, the possibility of BNP (5-32) and BNP (3-32) becoming new bio-markers for coronary restenosis was also demonstrated (Clinical Chemistry published May 13, 2013, as doi: 10.1373/clinchem.2013.203406).
Recent well-noted achievements
Cre
atio
n o
f Inn
ova
tion
Ce
nte
rs for A
dva
nc
ed
Inte
rdisc
iplin
ary R
ese
arc
h A
rea
s Prog
ram
4544
Yokohama City UniversityEstablishment of Research Center for Clinical Proteomics of Post-Translational Modifications
Development of analytical technology by combining technologies in the medical, pharmaceutical, scientific, and engineering fields
ORGANIZATION
Name Yokohama City University
U R L http: //www.yokohama-cu.ac.jp/shincho/
Address 22-2, Seto, Kanazawa-ku, Yokohama-shi, Kanagawa Prefecture TEL. 045-787-2441 FAX. 045-787-2025Overall Person-in-charge Katsuko Tanaka (Chairperson, Yokohama City University)
Researcher (Representative) Hisashi Hirano
Implementation Period FY2008 – FY2017
Collaborating Organizations : Medical ProteoScope Co.,
Ltd., Lion Corporation, FUJIFILM Corporation, Eisai Co., Ltd.,
FANCL Corporation, TOSOH Corporation, Sekisui Medical Co.,
Ltd, Toyama Chemical Co., Ltd., CellFree Sciences Co., Ltd.
■ 7th Year (FY2014)
Complete the development of a foundation to create innovative
analytical technologies that are necessary for the establishment
of the research center. Identify more than a thousand abnormal
PTM proteins related to diseases using these technologies. Dis-
cover the physiological functions and relationships with diseases
for a hundred or more of these proteins. Clarify the spatial struc-
ture of 10 or more abnormal PTM proteins to create a founda-
tion for drug design. Enable the development of drug targets
and biomarkers within a short period of time.
■ After Project Ends (around 2027)
Build a mutually complementary and innovative framework for
the university/the university hospital and companies to return
research achievements to society for a new social order while
fulfilling the traditional social roles of the university/the university
hospital in manpower development and in promoting basic and
applied research. Send young researchers nurtured at this center
to other research institutions to raise the research standard in
Japan and enhance international competitiveness in the field of
research on diseases that are caused by abnormal post-transla-
tional modifications in proteins.
■ 10th Year (FY2017)
Aim to commercialize mass spectrometers that can be used in
clinical examination and effectively detect abnormal post-trans-
lational modifications. Attempt drug design based on the results
of analysis of the spatial structure of abnormal PTM proteins.
Clarify the correlation between PTM level and patient condition,
applications towards the early discovery of diseases and pharma-
cokinetic studies, and possibility of predicting the treatment ef-
fects of developmental drugs. The creation of a discovery profile
for PTM proteins will open up a path to innovative personalized
medicine.
Collaboration System1
2 Overall Concept
The proteomics, medical, and engineering
research teams of Yokohama City University
and companies that possess advanced ana-
lytical technologies aim to collaborate with
one another in creating a medical research
center for clinical proteomics of post-transla-
tional modifications. The center will develop
high-throughput technologies that can detect
post-translational modifications in proteins
at a high sensitivity, and search for proteins
that will become diagnosis markers and drug
targets by comprehensive analysis on a large
scale of relationship between diseases and
post-translationally modified (PTM) proteins
at the molecular level. In addition to evalu-
ating the proteins discovered using genome
analysis, in vivo imaging techniques, and the
like, development of innovative assay meth-
ods for diagnostic markers will also be carried
out. Furthermore, the spatial structure of
the drug targets will be analyzed and drug
design will be carried out with the aim of de-
veloping new drugs. A new research center
will be formed through the construction of
a new Advanced Medical Research Center
building together with the establishment of
research laboratories for bioinformatics and
in vivo synthesis of proteins, and also through
supporting junior research teams, conducting
symposiums, and the like.
New building of the Advanced Medical Research Center
(construction completed in Dec 2012)
( )Professor, Director of the Advanced Medical Research Center of Yokohama City University
RESEARCH THEME
4746
Yokohama City UniversityEstablishment of Research Center for Clinical Proteomics of Post-Translational Modifications
1 Development of basic technologies and biomarkers
Develop advanced technologies for mainly mass spec-
trometry that are capable of analyzing the relationship
between diseases and abnormal PTM proteins. With this
as a foundation, carry out a comprehensive and large-
scale analysis of proteins whose expression fluctuates in
accordance with the disease using specimens from pa-
tients suffering from cancer, mental disorders, immuno-
logical diseases, and the like so as to advance the search
for biomarkers and drug target proteins.
Social Value The possibility of this leading to the devel-
opment of diagnostic and treatment methods for high
profile diseases such as cancer, lifestyle diseases, and the
like is high.
Economic Value Commercialization of analysis is possible
through the development of analytical technologies and
sales of analytical equipments.
Expected Market Scale/Expected Achievement Period
2.34 billion yen/10 years after end of implementation
period
Results to Date Basic technologies for the research
center were developed in the first half of the project.
The technology to detect and identify 3,000 plasma
proteins, the technology to detect and identify more
than 2,000 phosphorylated proteins and 4,000–6,000
phosphorylated sites using a mass spectrometer with
an improved scanning method to analyze quantitatively
phosphorylated peptides have been established. The
technology to monitor phosphorylated proteins using
affinity electrophoresis and a new post-translational
modified peptide dissociation method (electron capture
dissociation method and hydrogen atom transfer dissoci-
ation method) have been developed. Large-scale analysis
of post-translationally modifications such as GPI anchor
addition, acetylation, glycosylation, myristoylation, meth-
ylation, and ubiquitylation has also been made possible.
Research to detect and identify abnormal PTM proteins
using these technologies and to investigate their rela-
tionship with functions and disease is on-going.
3 Development of functional foods and cosmetics
Research to investigate the action mechanism of func-
tional foods like lactoferrin that have an effect of lower-
ing visceral fat is being carried out using proteomic tech-
nique. Research to discover new biomarkers that target
proteins related to the skin and health condition of the
whole body and research that aims to apply them to skin
diagnosis technologies and high-precision counseling are
also being carried out.
Social Value This will lead to the creation of functional
products useful for health promotion.
Economic Value Functional products with high economic
value can be sold through patent acquisition.
Expected Market Scale/Expected Achievement Period
2 billion yen/10 years after end of implementation period
Results to Date The action mechanism of functional
foods like lactoferrin that have an effect of lowering vis-
ceral fat has been analyzed using proteomic techniques.
The role that lactoferrin plays in the expression control of
important proteins involved in lipolysis and the stimula-
tion of the cAMP signaling pathway, which has been the
general lipolysis route to date have also become clearer.
Research to analyze the functional peptides that appear
in blood and reflect the health condition of the entire
body including skin after collagen intake is also on-go-
ing.
Development of diagnostic and treatment drugs for cancer, mental disorders, and immunolog-ical diseases
In addition to analyzing the functions of the proteins and
the correlation between disease and abnormal PTM pro-
teins identified in the patient specimens, model cells, and
the like, carry out research to evaluate and verify their
usefulness as biomarkers and drug target molecules, and
on the discovery of drug compounds that target abnor-
mal post-translational modifications in proteins related to
the disease.
Social Value The possibility of this leading to the devel-
opment of diagnostic and treatment methods for high
profile diseases such as cancer, neuropsychiatric disor-
ders, and the like is high.
Economic Value The possibility of commercializing drug
targets and biomarkers using 1/10–1/50 of the time and
efforts previously required is high. New drugs can be
developed and economic value can be added through
patent acquisition.
Expected Market Scale/Expected Achievement Period
303.6 billion yen/10 years after end of implementation
period
Collaborating Organizations : Medical ProteoScope Co., Ltd., TOSOH Corporation, Sekisui Medical Co., Ltd.
Collaborating Organizations : Lion Corporation, FANCL Corporation
Collaborating Organizations : FUJIFILM Corporation, Eisai Co., Ltd., Toyama Chemical Co., Ltd., LTD, CellFree Sciences Co., Ltd.
Results to Date Abnormal PTM proteins related to can-
cer, neuropsychiatric disorders, and the like have been
detected and identified using basic technologies that
have been developed. The relationship between disease
and detected proteins has also been verified, and po-
tential biomarker proteins that can be used in diagnosis
have been discovered. Furthermore, many proteins that
have a high possibility of becoming drug targets have
been identified. Meanwhile, significant results have been
obtained in the screening of drug compounds that target
proteins related to prostate cancer, HIV, intractable men-
tal disorder, rheumatoid arthritis, Huntington’s chorea,
medulloblastoma, and the like.
2
4948
Cre
atio
n o
f Inn
ova
tion
Ce
nte
rs for A
dva
nc
ed
Inte
rdisc
iplin
ary R
ese
arc
h A
rea
s Prog
ram
4948
National Institute of Advanced Industrial Science and Technology (AIST)Vertically Integrated Center for Technologies of Optical Routing toward Ideal Energy Savings (VICTORIES)
ORGANIZATION
Name National Institute of Advanced Industrial Science and Technology (AIST)
U R L http: //www.aist-victories.org/
Address Central 2, 1-1-1, Umezono, Tsukuba-shi, Ibaraki Prefecture TEL. 029-861-5254 FAX. 029-861-5255
R&D based on the vertical integration of technologies ranging from devices to system devices to network resource management
Overall Person-in-charge Ryoji Chubachi
Researcher (Representative) Shu Namiki (Director, Network Photonics Research Center)
Implementation Period FY2008 – FY2017
Collaborating Organizations : Nippon Telegraph and Tele-
phone Corporation, Fujitsu Laboratories Ltd., Furukawa Electric
Co., Ltd., Trimatiz Ltd., NEC Corporation, Fujitsu Ltd, Fujikura
Ltd., Alnair Labs Corporation, Sumitomo Electric Industries,
Ltd., Kitanihon Electric Cable Co., Ltd.
■ 7th Year (FY2014)
1 Complete the development of basic technologies for dynamic
optical path networks. Create transmission path optimization
equipment and time division multiplexing switches.
2 Carry out an actual operational demonstration of an optical
path network in the Tsukuba region using developmental tech-
nologies to verify low power consumption and large transmission
capacity.
■ After Project Ends (around 2023)
1 Growing in the use of dynamic optical path networks in actual
networks.
2 Promote research and development in communication tech-
nologies that can meet the requirements of society as an innova-
tion center based on the technologies cultivated in the research
center.
■ 10th Year (FY2017)
1 Upgrade the developmental technologies and create products
such as dynamic ROADM, wavelength selection switches, and
small-scale matrix switches.
2 Verify the ultra-low power consumption and convenience of
a dynamic optical path network in applications such as video
transmission through a field verification test over a wide area.
Collaboration System1
2 Overall Concept
In recent years, the volume of information
flowing through networks has increased rap-
idly, and thus the power consumption of the
entire network, including routers, has also
been increasing. To realize an information
society that can continue to grow on a sus-
tainable basis, it is crucial to drastically reduce
the energy consumed by networks. This re-
search center aims to resolve this problem by
developing a dynamic optical path network
technology whose energy efficiency is on 3–4
orders of magnitude higher than traditional
networks.
This is a new type of network that dynami-
cally provides an optical path to connect ter-
minal points between users through optical
switches. In order to realize this, the National
Institute of Advanced Industrial Science and
Technology has formed an R&D center to-
gether with ten collaborating organizations
to vertically integrate technologies such as
optical switches, system devices, network ar-
chitecture, and control systems. Development
of international researchers who are capable
of envisioning a wide scope on technologies
in areas ranging from devices to architecture
will also be carried out in the center.
( )President, National Institute of Advanced Industrial Science and Technology
RESEARCH THEME
5150
National Institute of Advanced Industrial Science and Technology (AIST)Vertically Integrated Center for Technologies of Optical Routing toward Ideal Energy Savings (VICTORIES)
1 Development of Dynamic Optical Path Network
Study the architecture of a dynamic optical path network
that operates with an improvement in energy efficiency
over that of current networks on an order of 3–4 digits,
integrate the component technologies, and carry out val-
idation of the network.
Social Value Realize an information society that is able
to grow sustainably and in which large amounts of data,
such as for high definition images, can be used exten-
sively without being constrained by energy consumption
so as to change the economy, society, and living environ-
ment
Economic Value A network-related market to achieve an
ultra-large capacity at ultra-low energy consumption will
be formed. New applications markets will emerge, with
a great variety such as telepresence, ultra-high-definition
video-on-demand, etc..
Expected Market Scale/Expected Achievement Period
Approximately 1.2 trillion yen/10 years after end of im-
plementation period (in Japan)
Results to Date A study on the basic functions and con-
figuration of the nodes required for a dynamic optical
path network has been completed, and the construction
of a test bed has been started within the campus of the
AIST. The design based on a regular grid topology with 3
x 3 core nodes is ongoing, and a large-scale demonstra-
tion test to transmit an ultra high-definition 8K resolu-
tion video in real time will be carried out in Oct 2014.
Collaborating Organizations : Nippon Telegraph and Telephone Corporation, Fujitsu Laboratories Ltd., Furukawa Electric Co., Ltd., Trimatiz Ltd.,
NEC Corporation, Fujitsu Ltd, Fujikura Ltd., Alnair Labs Corporation, Sumitomo Electric Industries, Ltd., Kitanihon Electric Cable Co., Ltd.
3 Optical path processor
Develop an optical matrix switch based on silicon pho-
tonics that switches the optical path dynamically at the
fiber level and wavelength selection switches that switch
the optical path at the wavelength level.
Social Value As targeted in the overall concept, an in-
formation society that can grow sustainably will be real-
ized through the development of new switches.
Economic Value A new network-related market for opti-
cal devices to achieve ultra-large capacities at ultra-low
energy consumption will be formed.
Expected Market Scale/Expected Achievement Period
100 billion yen/10 years after end of implementation pe-
riod (in Japan)
Results to Date The world’s smallest PILOSS 8 x 8 optical
matrix switch has been produced successfully and its ba-
sic operations and performance have been verified.
Collaborating Organizations : Fujitsu Laboratories Ltd., NEC Corporation, Furukawa Electric Co., Ltd., Kitanihon Electric Cable Co., Ltd.
Collaborating Organizations : Nippon Telegraph and Telephone Corporation, NEC Corporation, Fujitsu Ltd, Sumitomo Electric Industries, Ltd.,
Furukawa Electric Co., Ltd., Trimatiz Ltd., Fujikura Ltd., Alnair Labs Corporation, Fujitsu Laboratories Ltd.
Schematic illustration of test bed
2 Network devices
Development of dynamic optical node devices capable of
supporting data in diverse capacities, and technologies
for the integrated management of networks and storage
as well as for the optimization of network transmission
paths will be carried out.
Social Value As targeted in the overall concept, an in-
formation society that can grow sustainably will be real-
ized through the development of new network devices.
Economic Value A network-related market to achieve ul-
tra-large capacities at ultra-low energy consumption will
be formed.
Expected Market Scale/Expected Achievement Period
Approximately 1.1 trillion yen/10 years after end of im-
plementation period (in Japan)
Results to Date The basic operation of a multi-granular
-hierarchical node system has been verified using dy-
namic modules such as optical switches and wavelength
selective switches. The intermediate control interface
for efficiently controlling the node system has also been
defined, and been applying to control many different de-
vices modules.
Dynamic display of multi-granular, multi-hierarchical node (AIST Open Lab 2013)
The world’s smallest PILOSS 8×8 optical matrix switch
5352
Cre
atio
n o
f Inn
ova
tion
Ce
nte
rs for A
dva
nc
ed
Inte
rdisc
iplin
ary R
ese
arc
h A
rea
s Prog
ram
5352
Kobe UniversityInnovative Bio Production Kobe (iBioK)
ORGANIZATION
Name Kobe University
Address 1-1, Rokkodai-cho, Nada-ku, Kobe-shi, Hyogo Prefecture TEL. 078-803-5340 FAX. 078-803-5349
Interdisciplinary research that combines agriculture and engineering with the aim of material production (bio-production) that makes use of bio-resources as effectively as possible
Overall Person-in-charge Hideki Fukuda (President, Kobe University)
Researcher (Representative) Akihiko Kondo (Professor, Graduate School of Engineering)
Implementation Period FY2008 – FY2018
Collaborating Organizations : ASAHI KASEI CHEMICALS
CORPORATION, EZAKI GLICO CO., LTD., Kaneka Corpora-
tion, Gekkeikan Sake Company, Ltd., COSMO OIL CO., LTD.,
DAICEL CORPORATION, TEIJIN LIMITED, Nagase & Co., Ltd.,
NITTO DENKO CORPORATION, NIPPON SHOKUBAI CO., LTD.,
NIPPON PAPER INDUSTRIES CO., LTD., Bio-energy Corporation,
Fujicco Co., Ltd., Mitsui Chemicals, INC.
■ 7th Year (FY2015)
1 Collaborate with 5 or more research institutions overseas and
develop at least one of them to the national project level.
2 Partner with 14 collaborating organizations and aim to estab-
lish scale-up technologies for producing materials from biomass
for 6 or more of the target materials.
3 Aim to establish a “Graduate School of Bio-Refinery” that
integrates the two disciplines in the Graduate School of Agricul-
tural Science and Graduate School of Engineering based on the
achievements up to the 7th year.
■ After Project Ends (around 2019)
At the end of the implementation period for the research center,
a “Kobe University Bio-Refinery Organization” will be established
as an external body to manage the royalties received from com-
panies for the use of intellectual property that has been created
by this center as operational funds. Collaborative research will
be further widened to grow the center sustainably. “Joint Tech-
nology Groups” will also be established with multiple corporate
organizations for commercialization purposes.
■ 10th Year (FY2018)
1 Implement material production at the bench scale level at all
14 companies participating in the conceptual plan for the cre-
ation of the research center.
2 Aim to collaborate with 10 or more research institutions in
Europe, the U.S., and Asia, and establish the international stand-
ing of this research center.
3 Turn out personnel with recognized research skills and corpo-
rate adaptability in the business world and establish the social
recognition of this research center.
Collaboration System1
2 Overall Concept
This center aims to create a sustainable,
low-carbon society through green innovations
using advanced biotechnologies to com-
mercialize the bio-production of important
bio-products such as next-generation fuel,
synthesized raw materials, bio-plastics, bio-fi-
bers, and bio-fine chemicals from renewable
biomass resources. “Research Engines” in 6
core research areas that boast the originality
and eminence of Kobe University will be es-
tablished and promoted through industry-in-
dustry-academia partnerships. In addition to
creating process innovations and commer-
cializing bio-products through an integrated
bio-process, product innovation to create
new materials will also be carried out. Person-
nel who are capable of making assessments
based on a comprehensive understanding of
bio-production while taking global circum-
stances into account will also be nurtured.
Furthermore, research interaction for the
purpose of promoting industry-industry-aca-
demia collaboration and the “Bio-Restaurant”
intellectual property system will be strongly
promoted.
U R L http: //www.org.kobe-u.ac.jp/bioproduction/
RESEARCH THEME
5554
Kobe UniversityInnovative Bio Production Kobe (iBioK)
4 Development of Basic Technologies
Companies aim to commercialize products required to
build integrated bio-processes for biomass production,
pre-processing, bio-processing, film processing, and the
like, among core basic technologies developed by Kobe
University.
Results to Date Development of these basic technolo-
gies is ongoing, and application of these technologies
towards bio-production in collaboration with other com-
panies has reached the doorstep of commercialization.
The establishment of bio-production technology to produce various bio-products from renewable biomass involves the
development of green innovations for large-scale conversion of products made from petroleum in chemical factories
to bio-products. With Kobe University, which leads Japan in bio-refinery research, playing a leading role, this research
center is an initiative to create Japan’s largest bio-refinery for the commercialization of key bio-products through indus-
try-academia collaboration. By creating and closely promoting six key research engines” that integrate the unique lead-
ing technologies of Kobe University through collaboration between the Agriculture and Engineering faculties, Bio-pro-
duction will be institutionalized as an advanced interdisciplinary research domain.
2 Bio-plastics, Bio-fibers
Aim for the bio-production of organic acids, diamines,
amino acids, and aromatic compounds that have been
selected as key chemicals. Furthermore, develop environ-
mentally friendly technology to synthesize bio-plastics
and bio-fibers.
Results to Date Nine types of compounds have been
produced successfully to date and scale-up studies are in
progress. Productivity for certain target compounds has
been improved by 15 times or more. Appropriate targets
for market launch have been set for each compound,
and steady progress in research is being made.
Collaborating Organizations : DAICEL CORPORATION, TEIJIN LIMITED, Bio-energy Corporation, Mitsui Chemicals, INC.
1 Next Generation Fuel, Synthesized Raw Materials
Aim for the bio-production of alcohols and diols that
have been selected as key chemicals.
Results to Date Four types of compounds have been
produced successfully to date, and scale-up studies are in
progress. Productivity for certain target compounds has
been improved by 40 times or more. Moreover, bench
production tests at a 90-L scale are also ongoing, with
steady progress being made towards commercialization.
Collaborating Organizations : ASAHI KASEI CHEMICALS CORPORATION, NIPPON SHOKUBAI CO., LTD.
3 Bio-fine Chemicals
Aim for the bio-production of functional sugars, useful
inositols, function peptides, functional phospholipids,
etc.
Results to Date Ten or more types of compounds have
been produced successfully thus far, and functional eval-
uations and scale-up studies are in-progress. Technology
to scale up production of certain target compounds to a
scale of 900 L has been established. Appropriate targets
for market launch have been set for each compound,
and steady progress in research is being made.
Collaborating Organizations : EZAKI GLICO CO., LTD., Kaneka Corporation, Gekkeikan Sake Company, Ltd., COSMO OIL CO., LTD., Nagase
& Co., Ltd., Fujicco Co., Ltd.
Social Value This will have a great impact on the foun-
dation for the sustainable development of the country in
future, such as through release from dependence on oil,
energy conversion, significant reduction in CO2 emissions,
resource and energy security, and stimulation of agricul-
ture, forestry, and fishery.
Economic Value Based on global trends in the market
for bio-products, large-scale expansion of bio-fuels and
bio-processed products is expected sometime from 2020
to 2030. An enormous market can be created by focus-
ing on research and development in preparation for this.
Collaborating Organizations : ASAHI KASEI CHEMICALS CORPORATION, Gekkeikan Sake Company, Ltd., Nagase & Co., Ltd., NITTO DENKO CORPORATION, NIPPON PAPER INDUSTRIES CO., LTD., Bio-energy Corporation
12
At the “Innovative Bio Production Kobe (iBioK)” center, im-portant bio-products are rolled out in the market to realize green innovations and divert raw materials used from petro-leum to biomass.
Mass-produced next-generation fuel, synthesized raw mate-rials, bio-plastics, and bio-fibers, as well as high value-added bio-fine chemicals are three of the targeted product groups to be produced from biomass. Basic technologies that sup-port bio-production will also be commercialized so that they can be applied to even more chemicals.
Kobe University is the leading bio-refinery research authority in Japan. The agriculture and engineering faculties of the university will collaborate with 14 leading chemical compa-nies in Japan to build an international research center for accelerating the development of green innovations. Besides establishing the basic technologies for bio-production, the center will aim to commercialize important bio-products and become the core center for the formation of bio-combinates.
So far, the center has succeeded in raising the production volume of higher-order alcohols and organic acids by several times to several tens of times, and steady progress has been made towards commercialization through scale-up opera-tions. New fine chemicals and building blocks that will serve as new materials continue to be discovered in succession,
leading to the creation of new industries and new markets.
The 14 collaborating organizations are not simply a col-lection of companies. With Kobe University at the center, they collaborate closely with one another while shouldering different roles to form bio-combinates. This research center is an initiative to create Japan’s largest bio-refinery through industry-academia collaboration.
“Innovative Bio Production Kobe (iBioK)”
In-Depth Focus 12 Kobe University
11
In-Depth Focus 11
Vertically Integrated Center for Technologies of Optical Routing toward Ideal Energy Savings (VICTORIES)
The world’s smallest 8 × 8 optical matrix switch successfully fabricated
(a) Optical microscope image of 8 × 8 optical matrix switch. (b) Mounted switch chip on ceramic interposer.
An optical matrix switch switches optical paths at the
fiber level, which is one of the most important compo-
nents comprising the dynamic optical path network. At
the National Institute of Advanced Industrial Science and
Technology, the world’s smallest 8 × 8 optical matrix
switch (shown in the figure below) has been fabricated
successfully using Si photonics technology. The size of the
fabricated optical matrix switch is 2.4×3.5 mm2, which
is 1/550 as small as that of a traditional optical matrix
switch based on silica. This achievement has been accept-
ed as a post deadline paper in the European Conference
and Exhibition on Optical Communication, which is one
of the world’s most authoritative international confer-
ences for optical communications, and acknowledged as
the latest key achievement in this area (K. Suzuki, et al., ECOC 2013, PD2.D.2.).
In-Depth Focus 10 Yokohama City University
Establishment of Research Center for Clinical Proteomics of Post-Translational Modifications
The synaptic delivery of AMPA receptors is an attractive
event as a molecular basis of neural plasticity. However,
clinical application of AMPA receptor mediated synaptic
plasticity is still very limited. Through various post-transla-
tional modifications to control the synaptic trafficking of
AMPA receptors, Professor Takuya Takahashi et al. have
shown the relationship between the synaptic delivery of
AMPA receptors and mental disorders and carried out
research for the clinical applications such as drug discov-
ery and diagnosis. In order to examine the mechanisms
of a variety of mental disorders that are caused by child
abuse (eg. neglect), Professor Takahashi et al. examined
the effect of early social isolation on the synaptic delivery
of AMPA receptors. They found that early social isolation
attenuates experience-driven synaptic AMPA receptor
delivery through the abnormal post-translational modifi-
cation detected by the mass
spectrometer in this research
center. Furthermore, they found
abnormal c ircuit formation
and behaviours in isolated animals (Miyazaki et al. J. Clin.
Invest. 2012). Meanwhile, a rich environment facilitates
synaptic AMPA receptor delivery via the activation of sero-
tonergic system through the changes in phosphorylation
of AMPA receptors (Jitsuki et al. Neuron 2011). Further-
more, synaptic AMPA receptor delivery is required for the
formation of fear memory (Mitsushima et al. PNAS 2011,
Mitsushima et al. 2013 Nature Communications). Based
on these findings, leading compounds that control neural
plasticity were identified in cooperation with the organiza-
tions involved in this research center. This potentially leads
to clinical applications.
Pursuing the link between brain plasticity and neuropsychiatric disorders
10
Aim for the creation of a center that can conduct comprehensive research on the relationship between diseases and post-translational modifications in proteins using advanced proteomics analytical technologies.
Professor Takahashi
Kyoto University National Institute of Advanced Industrial Science and Technology (AIST)In-Depth Focus 09
09
Center for Innovation in Immunoregulatory Technology and Therapeutics (AK Project)
Under the slogan "Best Drugs on Best Science," Kyoto Univer-
sity and Astellas Pharma Inc. are collaborating to create new
innovative drugs in the immunology area including allergy such
as atopic dermatitis and pollinosis, autoimmune disorders such
as rheumatoid arthritis and SLE, cancer immunotherapy, and
immunosuppression in regenerative medicine.
In Japan, Kobe University is the only large research center for industry-academia collaboration
This center is the first in the world to promote everything from the development of an integrated bio-process to the formation of bio-combinates through industry-industry-academia collaboration
5756